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Summary 
 
SUMMARY  
 
Friedreich’s ataxia (FRDA) is an autosomal recessive neurodegenerative 
disease caused by mutations in the frataxin gene (FXN), which lead to reduced levels 
of the essential mitochondrial protein frataxin (FXN). Currently there is no effective 
treatment or cure.  
Recently, a clinical trial for intractable pain (Dr Fink, Michigan 2011) 
demonstrated that delivery of a therapeutic transgene by non-replicative genomic 
herpes simplex virus type-1 (HSV-1) vectors to the dorsal root ganglia (DRG), 
principal target of gene therapy for Friedreich’s ataxia, did not produce any vector-
related adverse effects. Following on from these encouraging results and considering 
previous observations of our laboratory demonstrating sustained expression driven by 
the FXN genomic locus, we aim to develop a gene therapy for FRDA neuropathology. 
Our approach has consisted on the construction and preliminary 
characterization of a high capacity nonreplicative genomic HSV-1 vector 
(27_4_Or2_β22 FXNinlZ vector) carrying a reduced version of the human FXN 
genomic locus, comprising the 5 kb promoter and the FXN cDNA with the inclusion 
of intron 1. We show that the nonreplicative HSV-1 genomic vector deleted for 23 kb 
maintains its growth capacity and the FXN transgene cassette contains the elements 
necessary to preserve physiological neuronal regulation of human FXN expression. 
Transduction of cultured fetal rat DRG neurons with the 27_4_Or2_β22 FXNinlZ 
vector results in sustained expression of human FXN transcripts and FXN protein. Rat 
footpad inoculation with the 27_4_Or2_β22 FXNinlZ vector results in human FXN 
transgene delivery to the DRG, with expression persisting for at least 1 month.  
Our results support the feasibility of using this vector for sustained neuronal 
expression of human FXN for future FRDA gene therapy. 
 
 
Resumen 
RESUMEN 
 
La ataxia de Friedreich (AF) es una enfermedad neurodegenerativa causada 
por una mutación en el gen de la frataxina (FXN), que genera una deficiencia de la 
proteína mitocondrial esencial frataxina (FXN). Esta enfermedad presenta un patrón 
de herencia autosómica recesiva y en la actualidad no se dispone de ninguna terapia 
efectiva para su tratamiento o cura.  
Recientemente, un ensayo clínico para terapia del dolor (Dr Fink, Michigan 
2011) demuestra que la administración de vectores genómicos no replicativos 
derivados del virus del herpes simple tipo 1 (VHS-1) en los ganglios de las raíces 
dorsales, principal diana para terapia génica de AF, no desencadena ningún efecto 
adverso. Basándonos en  estos resultados y en experimentos previos de nuestro 
laboratorio que demuestran que mediante el uso del locus genómico de FXN se 
consigue una expresión sostenida de FXN, nuestro objetivo es el desarrollo de una 
terapia génica para el tratamiento de la neuropatología de AF. 
El abordaje de este trabajo ha consistido en la generación y caracterización 
preliminar de un vector genómico no replicativo y de gran capacidad derivado del 
VHS-1 (vector 27_4_Or2_β22 FXNinlZ) que contiene una versión reducida del locus 
genómico humano de FXN: el promotor de 5 kb seguido de la secuencia  del ADN 
complementario manteniendo el intrón 1. En este estudio se observa que: i) tras 
eliminar 23 kb  del vector genómico no replicativo derivado del VHS-1 se mantiene 
su capacidad de crecimiento; ii) la versión reducida del locus FXN contiene los 
elementos necesarios para preservar la regulación fisiológica de la expresión de FXN 
humana en neuronas; iii) tras la transducción in vitro de neuronas de los ganglios de 
las raíces dorsales de fetos de ratas con el vector 27_4_Or2_β22 FXNinlZ, hay tanto 
una transcripción como una traducción sostenida de FXN. Finalmente, los 
experimentos in vivo demuestran que la inoculación intraplantar de nuestro vector en 
ratas permite la detección de la expresión de FXN humana en los ganglios de la raíces 
dorsales, la cual se mantiene al menos 1 mes tras la inoculación. 
Nuestros resultados apoyan la idea del uso de nuestro vector 27_4_Or2_β22 
FXNinlZ para la expresión a largo plazo de FXN humana en el desarrollo de una 
futura terapia génica para el tratamiento de AF. 
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1. ABBREVIATIONS 
 
AAV Adeno-associated virus 
ATP Adenosine triphosphate 
BAC Bacterial artificial chromosome 
BDNF Brain-derived neurotropic factor  
cDNA Complementary DNA 
CMV Cytomegalovirus 
CPE Cytopathic effects 
DAB 3, 3’-Diaminobenzidine 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DRG Dorsal root ganglia 
dNTPs Deoxyribonucleotide triphosphates 
Dox Doxycycline 
dsDNA Double stranded DNA 
DTT Dithiothreitol 
E Early  
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
FBS Fetal bovine serum 
FDU fluoro-2deoxy-uridine 
 Fe–S Iron–sulfur 
FRDA Friedreich’s ataxia 
FXN Frataxin 
GAA Guanine-adenine-adenine 
GFP Green fluorescent protein 
HCF  Host cell factor 
HDAC Histone deacetylase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
hFXN Human frataxin 
HRP Horseradish peroxidase  
HSV Herpes simplex virus 
ICP  Infected cell polypeptide 
IE  Immediate early 
Abbreviations 
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IPTG Isopropyl β-D-l- thiogalactopyranoside 
IR Internal repeat 
kb Kilobase 
kDa Kilodalton 
L Late 
L4-6 Lumbar levels 4-6 
lacZ β-galactosidase 
LAP Latency associated promoters 
LAT Latency associated transcript 
LB Lysogeny Broth 
LV Lentivirus 
miRNA microRNA  
MOI Multiplicity of infection 
MPP Mitochondrial processing peptidase 
mRNA Messenger RNA 
NGF Nerve growth factor 
N-terminal Amino-terminal 
Oct-1 Octamer binding protein-1 
OD Optical density 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PBST Phosphate buffered saline with Tween 20 
PCR Polymerase chain reaction 
PDL poly-D-lysine 
PFA Paraformaldehyde 
Pfu Plaque forming units 
PTV1  Porcine teschovirus-1 
qRT-PCR Real time RT-PCR 
RNA Ribonucleic acid 
RNA Pol RNA polymerase 
RT-PCR Reverse transcription PCR 
SDS Sodium dodecyl sulfate 
SDS-PAGE SDS-Polyacrylamide gel electrophoresis 
SOC Super optimal broth with catabolite repression 
SV40 Simian vacuolating virus 40 
TAE Tris-acetate EDTA 
Abbreviations 
 5 
TALE  Transcription activator-like effector protein 
TSS Transcription start site 
TR Terminal repeat  
UV Ultraviolet 
VP Virion protein 
WT Wild-type 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
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2. INTRODUCTION 
2.1. Herpes Simplex Virus-1 (HSV-1) 
HSV-1 is a common human pathogen that belongs to the Herpesviridae 
family, a group of enveloped, double-stranded (ds) DNA viruses.1 Based on genome 
size and content, speed of replication, host range and cell types where latency is 
established, herpesviruses are classified into three subfamilies: Alpha-, Beta- and 
Gamma- herpesvirinae, of which HSV-1 belongs to the fast-growing, neurotropic 
Alphaherpesvirinae. Mainly transmitted by oral contact; HSV-1 lifelong infection is 
usually benign, and commonly associated with oral, perioral, genital, skin and 
mucous membrane lesions. In rare cases, HSV-1 is known to migrate to the brain and 
provoke viral encephalitis.2 On average, 90% of the adult population is seropositive 
for anti-HSV-1 antibodies. 
2.1.1. Structure of the virion  
The spherical HSV-1 virion has an approximate diameter of 180 nm and is 
formed by four main structural components: the external envelope, a cell membrane-
derived bilayer which includes several virus-encoded glycoproteins involved in 
attachment and entry of the virion into the host cell; the tegument, an amorphous 
layer containing virus-encoded proteins with structural and regulatory roles very 
important for efficient infection; an icosahedral nucleocapsid, composed of 162 
capsomers which are required for the packaging of the genome; and the dsDNA 
genome wound in an electron-dense core.3   
2.1.2. Life cycle   
HSV-1 exhibits two modes of life cycle: lytic, in highly replicative cells, and 
latent, in neuronal cell bodies (Figure 1). In epithelial cells of the skin or mucosa, 
following attachment to the target cell surface, the virion enters generally either by 
fusion of the virion envelope with the plasma membrane or through endosomes. The 
content of the tegument and the nucleocapsid is then released into the cytoplasm and 
transported via the host’s cytoskeleton elements to the nuclear pores. There, lytic 
growth is characterized by viral DNA replication and assembly of the viral DNA core 
and nucleocapsid, followed by envelopment of new virions at the nuclear membrane.  
Introduction 
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Finally mature virions are transported to the outer cell membrane through cellular 
vesicles. Lysis of the host cell releases the viral progeny.  
Virions, which during the course of infection gain access to sensory nerve 
terminals, undergo axonal retrograde transport from the nerve endings in peripheral 
tissue to neuronal cell bodies buried deep in the spinal cord where HSV-1 establishes 
life-long latency. 4 Periodic reactivation of the latent genome can occur spontaneously 
or in response to stimuli like ultraviolet (UV) light exposure, high temperature, fever, 
mental or physical trauma to the host 5,6, bringing infectious viral progeny back to the 
nerve endings through anterograde transport and provoking skin lesions or mucosal 
ulcers.7   
 
 
 
Figure 1. HSV-1 life cycle 
Through fusion of the viral envelope with the plasma membrane of an epithelial cell of the 
skin or mucosa, HSV-1 enters and releases the nucleocapsid and tegument into the 
cytoplasm. Transport of the nucleocapsid to the nucleus is mediated by the host cytoskeleton 
and the genome is injected into the nucleus through nuclear pores. Following lytic replication 
in the infected epithelia, progeny virions which contact nerve endings are carried by 
retrograde transport to the cell bodies of sensory neurons innervating the infection site. Upon 
arrival in the cell body, the virus either initiates lytic expression or enters latency. Periodic 
reactivation from latency can occur spontaneously or in response to a variety of stimuli, 
resulting in the production of progeny virions that are moved by anterograde transport back 
to the nerve terminal to re-infect new epithelial cells, which leads to asymptomatic shedding 
or recurrent lesions. 
Reactivation 
Lytic infection 
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axonal 
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axonal 
transport 
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replication 
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replication 
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2.1.3. Genome  
The HSV-1 genome is a linear, large and structurally complex dsDNA of 
around 152 kilobases (kb) (Figure 2). It is partitioned into two segments of unique 
sequences, the unique long (UL) and unique short (US), flanked by inverted repeat 
sequences (RL and RS with prefixes I or T denoting internal or terminal), which 
themselves are bounded by shorter repeated segments known as “a” sequences. The 
presence of the “a” sequences at the IRL/IRS junction and the termini of the linear 
genome, TRL and TRS, enables inversion of the orientation of UL and US regions 
relative to each other, producing four possible genomic isoforms at approximately 
equimolar levels.8 Moreover, the “a” sequences contain sites necessary for the 
packaging of viral DNA into the virion and in the TR region these sequences are 
asymmetrically partitioned and contain single base 3’ extensions which serve as 
cohesive ends to circularize the genome prior to initiation of DNA synthesis.9,10 DNA 
replication generally begins at specific sites on viral genomes known as origins of 
replication; three origins of replication have been identified within the HSV-1 
genome: one within the UL region (oriL) and two copies flanking the US region within 
the repeat sequences (oriS). The significance of the presence of three origins of 
replication in the HSV-1 genome still not well understood. Among the 80 virus-
encoded genes, approximately half of them have been described as dispensable for in 
vitro viral replication, but play significant roles in vivo in virus-host interactions.11,12   
 
 
 
Figure 2. Schematic representation of HSV-1 genome 
Schematic representation of the 152 kb double-stranded DNA genome of wild type HSV-1. 
The unique long (UL) and the unique short (US) segments are shown flanked by the internal 
repeat (IR) and the terminal repeat (TR) which themselves are bounded by the packaging 
signals (a and a’). The unique origin of replication oriL is present in the UL segment (L 
U
L5
4 
(I
C
P2
7)
 
 
    U
L5
 
 U
L8
 
U
L9
 
U
L1
2 
 
U
L2
   
    
U
L1
5 
U
L1
7 
U
L1
8 
U
L1
9 
U
L2
2 
 U
L2
5 
U
L2
6 
U
L2
7 
U
L2
8 
 U
L3
1 
U
L3
2 
U
L3
3 
U
L3
4 
U
L3
5 
U
L3
6 
U
L3
7 
U
L3
8 
U
L1
0 
  
U
L1
1 
U
L1
3 
  
U
L1
6 
 
U
L2
0 
 U
L2
3 
U
L3
9 
U
L4
0 
 
U
L1
   
 U
L6
 
U
L7
 
 
U
L3
   
 
 U
L4
 
U
L1
4 
 U
L4
1 
U
L4
3 
U
L4
4 
U
L4
5 
U
L4
6 
U
L4
7 U
L2
1 
U
L2
4 
U
L4
2 
U
L4
8 
U
L4
9 
 U
L5
3 
U
L5
2 
U
L5
0 
 
U
L5
1 
 
U
L5
5 
U
L5
6 
IC
P0
 IC
P3
4.
5 
IC
P0
 IC
P3
4.
5 
U
S1
  
(I
C
P2
2)
 
IC
P4
 
IC
P4
 
U
S1
2 
 
(I
C
P4
7)
 U
S7
 
U
S8
 
U
S9
 
U
S3
 
U
S1
1 U
S2
 
U
S4
 U
S5
 
U
S6
 
U
S1
0 
a’ 
TR L IR IR 
a 
S
a’ 
TR S
Essential genes 
Non-essential genes 
Immediate early gene 
Early gene 
Late gene 
Unknown  
Introduction 
 11 
enclosed by circle) and two copies of oriS (S enclosed by circle) are present flanking the US 
segment. The 80 genes expressed in lytic infection are indicated as essential or nonessential 
based on their requirement for viral replication in culture. Transcription of the viral genes 
occurs in three temporal phases after infection; immediate early (red lines), early (purple 
lines) and late (orange lines). The transcription stage of a few HSV-1 genes is not known 
(green lines). 
 
2.1.3.1. Genome expression  
Although HSV-1 depends on the transcriptional machinery of the host cell, 
the viral genome also encodes several proteins that modulate viral gene expression. 
HSV-1 gene products are synthesized in a coordinatedand sequentially ordered 
process. Based on the kinetics of their synthesis, three temporal groups of genes have 
been identified: immediate early (IE) or α genes, early (E) or β genes and late (L) or γ 
genes (Figure 3).13  
 
 
 
Figure 3. Expression and regulation of HSV-1 genes 
Schematic diagram of the HSV-1 gene expression cascades during productive infection. 
VP16 interacts with Oct-1 and HCF to transactivate immediate early gene transcription. With 
the exception of ICP47, which is mainly involved in host immune evasion, the immediate-
early gene products stimulate expression of early genes, which encode functions necessary 
for replication of the viral genome. Late genes are expressed after the initiation of DNA 
replication. Immediate early gene products thus regulate the coordinated expression of the 
HSV-1 genome. ICP4 and ICP27 are necessary for viral replication and transactivate the 
expression of early and late genes. ICP0 is a promiscuous transactivator of viral genes and in 
synergy with ICP4, transactivates early and late genes. ICP0 has nonetheless been described 
to be non essential for in vitro viral replication. ICP4 is also a repressor of ICP0 and its own 
transcription. Although ICP22 is dispensable for viral replication in some cell types, it is 
important for the optimal expression of late genes. 
 
The IE genes are the first to be transcribed in the absence of de novo viral 
protein synthesis, reaching a peak of expression between 2 to 4 hours post infection.13  
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The E genes, which encode products including enzymes and viral DNA-binding 
proteins necessary for replication, are transcribed only once IE genes have been 
expressed, and reach a peak of expression between 5 to 7 hours post infection.13 The 
L genes, which mainly encode the structural polypeptides of the virion, are finally 
transcribed after both IE gene expression and completion of DNA replication, and 
reach a peak of expression between 12 to 15 hours post infection.13   
The three groups of genes are also characterized by the structure of their 
promoter regions. Although IE promoters contain common eukaryotic cis-acting 
regulatory elements such as a TATA element and Sp1 response elements, the most 
remarkable feature of this type of promoters is the presence of cis-acting regulatory 
sequence motifs (consensus TAATGARAT, where R is a purine), responsible for the 
transactivation effect of virion protein 16 (VP16), a component of the viral tegument. 
Upon permissive infection of the host cell, VP16 is transported to the nucleus and 
activates transcription by binding, along with the cellular factor Oct1 and host cell 
factor (HCF), to the TAATGARAT element 14,15, followed by recruitment of the host 
RNA polymerase II transcription machinery to close proximity of IE promoters.16,17 
In contrast to IE promoters, early promoters contain a TATA box and transcription 
factor binding sites without the presence of virus-specific cis-acting regulatory 
elements18, while late promoters include only the TATA element and initiator 
elements.19,20   
 
2.1.3.2. Immediate early proteins 
Among the five IE proteins (Figure 3), also termed infected cell proteins 
(ICP)- 4, 27, 0, 22 and 47, ICP4 and ICP27 have been described as essential for viral 
productive infection due to their crucial requirement for progression from the 
transcription of IE genes to the transcription of the rest of the viral genome. 21,22 ICP4 
(encoded by a diploid gene) acts both as a transactivator at low-affinity sites and as a 
repressor at high-affinity sites at the transcription initiation signals of its own 
promoter and those of several other genes.23,24,25 ICP27 acts mainly at the post-
translational level by regulating the processing of viral and cellular mRNAs. 26,27,28   
Although ICP0 and ICP22 are considered as non-essential for viral growth, 
they enhance the transactivation of viral genes and are required for efficient lytic 
replication. In addition to the major role of ICP0 (encoded by a diploid gene) in viral 
gene transactivation and genome reactivation from latency, an important contribution 
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of this protein in productive infection is the suppression of host intrinsic and innate 
defence machinery to prevent silencing of the viral genome.29,30,31 ICP22, on the other 
hand, is involved in regulation of transcription of the viral genome through 
phosphorylation of cellular RNA polymerase II and reorganization of host cell 
molecular chaperones into nuclear inclusion bodies.32 The fifth IE protein, ICP47, 
also considered as non-essential for viral productive cycle, has been described as the 
only IE protein not involved in regulation of the viral genome expression. Instead, 
ICP47 interferes with host cell adaptive immunity by preventing major 
histocompatibility class I antigen presentation.33   
 
2.2. HSV-1 derived vectors  
Effective gene delivery is crucial for the success of gene therapy. The natural 
biology of HSV-1 makes it a promising tool for this purpose in the nervous system. 
In particular, this virus is capable of infecting both non-dividing and dividing cells 
from a wide range of hosts with high efficiency. It has evolved to be neurotropic; its 
survival strategy enables it to persist in neurons of immune-competent hosts in a 
lifelong, non-integrated latent state without causing insertional mutagenesis or 
disease. Notably, HSV-1 also has a large genome-packaging capacity (up to 152 kb), 
which widely exceeds that of most other viral vectors in current use.  
Two types of HSV-1 derived vectors for gene therapy can be distinguished 
depending on the target tissue and purpose of the gene delivery34,35,36,37: 1) 
replication-competent vectors, which are constructed to provoke toxicity (eg. for 
brain tumor treatment) using viruses carrying different attenuating mutations to 
restrict the spread and lytic replication of the virus only to actively dividing cells 
without harming normal tissues; 2) replicative-incompetent vectors, constructed for 
therapeutic gene transfer using viruses deleted or mutated for one or more essential 
viral genes, thus rendering them devoid of the capacity for lytic replication (Figure 
4).  
2.2.1. Replication incompetent vectors 
Replication-incompetent HSV-1 vectors, also known as recombinant 
replication-defective vectors, are disabled, nonpathogenic mutants unable to 
disseminate out of inoculated cells, but which like the wild type (WT) virus, are able 
to establish an intra-nuclear quiescent state in neurons. Two classes of these vectors 
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have been developed following different strategies: amplicon and genomic 
vectors.38,39,40   
 
 
 
Figure 4. Production of HSV-1 derived vectors  
Schematic diagram of the three different classes of HSV-1 vectors and their respective 
production strategies.  
a. Replication-competent vectors are attenuated by removal of neuropathogenic accessory 
genes for targeting of brain tumors without harming normal brain tissue. These vectors are 
propagated by infection of tumor cells.  
b. Replication-incompetent genomic vectors are deleted for one or more essential viral genes 
and must be grown in cell lines that complement these deleted functions in trans. Infection of 
non-complementing cells will not allow viral replication.  
c. Replication-incompetent amplicon vectors are plasmids that contain the HSV-1 origin of 
replication (oriS) and packaging (a) sequences. Two main strategies can be performed to 
produce amplicon vectors: transfection of the amplicon DNA and infection with a defective 
helper virus, which supplies viral functions needed to replicate the amplicon DNA in 
complementing cells, thus generating helper and amplicon viruses; or co-transfection of the 
amplicon DNA and a bacterial artificial chromosome (BAC) DNA carrying the HSV-1 
genome without the packaging (Δa) sequences, thus generating helper-free amplicon viruses. 
Two main helper systems have been developed: using replication-defective helper viruses, 
which are deleted for an essential gene; or using the HSV-1 LaLdeltaJ helper viruses which 
in addition to be deleted for the essential ICP4 gene and the ICP34.5 gene, carry a unique 
and ectopic packaging signal flanked by two loxP sites. The LaLdeltaJ helper viruses supply 
viral functions needed to replicate the amplicon DNA in complementing cells expressing Cre 
and to generate amplicon viruses less contaminated with helper viruses. 
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2.2.1.1. Amplicon vectors 
Consecutive high-dose passages of HSV-1 result in generation of defective 
viral particles which interfere with viral stocks and carry only a minimal subset of 
DNA sequences from the WT genome. Genomes from these defective particles 
include the HSV-1 origin of DNA replication and cleavage/packaging site but have 
lost the complete set of lytic functions needed to support productive virus 
replication.41 These observations led to the creation of amplicon vectors, plasmids 
carrying these minimal HSV-1 sequences that allow them to be packaged into virus 
particles with the aid of replication-defective HSV-1 mutants (helper viruses) or 
packaging-defective HSV-1 genomes cloned as plasmids.38,42 The absence of almost 
the entire viral genome, and therefore the lack of expression of any viral proteins, has 
conferred upon these vectors ideal features for gene transfer: transgene capacity up to 
around 150 kb of foreign DNA; absence of cytotoxicity and pathogenesis; and as 
simple plasmids, easy handling and construction. However, complexity of their 
production remains a major obstacle to overcome for large-scale production of high 
titer amplicon vectors.  
 
2.2.1.2. Genomic vectors 
A second strategy for the generation of nonreplicative HSV-1 derived vectors 
takes advantage of the hierarchical cascade organization of gene expression from the 
viral genome. Two major approaches have been followed to inactivate the virus for 
the generation of so-called genomic vectors by disabling components which initiate 
the lytic cycle: the VP16 protein and IE gene expression.   
In the first case, mutations have been introduced to abolish the capacity of the 
VP16 protein to transactivate IE gene expression while maintaining its essential 
structural function required for virion assembly.43,44 Although propagation of such 
vectors was initially achieved by growth in cells supplemented with a compound with 
stimulatory activity of IE gene expression (Hydroxymethyl bisacetamide (HMBA))45,  
a more efficient system has been developed using cell lines expressing the equine 
herpes virus homolog of VP16, following the discovery that this protein can 
transactivate the HSV-1 IE genes without being packaged into HSV-1 virions.46   
The second approach for generating nonreplicative genomic vectors is based 
on the fact that deletion of the IE gene ICP4 results in an impaired expression of early 
and late gene products and does not produce infectious viral progeny.23 Nonetheless, 
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this mutant is highly cytotoxic.47 Deletion of the other essential IE gene ICP27 has 
been shown to drastically further reduce levels of early and late gene expression.48  
However infection with such modified HSV-1 viruses remains toxic to cells in 
culture, which was hypothesized a consequence of the expression of the other IE gene 
products ICP0 and ICP22.   
After additional inactivation of either ICP22 49 or ICP0 50 decreased levels of 
cytotoxicity were observed, thus forming the basis for the generation of multiply 
deleted HSV-1 genomic vectors51 including a mutant which was simultaneously 
deleted for the five IE genes.52 This mutant was shown by several criteria to be non-
toxic in all infected cell types and silent for transcription of nearly all the viral genes. 
Almost 30 years of development culminated in the first use of a nonreplicative 
genomic HSV-1 vector inactivated for ICP4, ICP27, ICP22, and ICP47, in human 
clinical trials for treatment of cancer-related pain.53 This study demonstrated that the 
vector, which has now been administered to more than 30 patients, did not produce 
any vector-related adverse effects when delivered to the dorsal root ganglia (DRG) by 
skin inoculation. 
2.2.1.2.1. Production of genomic vectors: complementing cell lines 
Since nonreplicative genomic vectors are deleted for genes essential for viral 
growth in culture, the generation of complementing cell lines, which provide the 
missing gene products in trans, is clearly a critical step to produce and amplify these 
vectors. However, constitutive cellular expression of many of these essential 
functions is cytotoxic, thus posing an obstacle for generating stable cell lines 
modified with these genes. Nonetheless, this problem has been overcome by using 
inducible promoters that are responsive to viral infection, such as some of the HSV-1 
IE promoters. In uninfected cells stably transfected by these promoters, the 
expression of the complementing protein is shut off, and only activated by the virion 
protein VP16 upon infection. However, engineering of such complementing cell lines 
remains a challenge due to the lack of control over the copy number of 
complementing genes that will integrate, or their position in the cellular genome; both 
of these variables affect the final expression level and kinetics of these genes.  
Vero, BHK and U2OS have been some of the cell lines engineered to 
complement ICP4, ICP27 and ICP0 alone or in combination46,48,50,51,52,54,55,56  
although no cell line complementing the absence of all the IE genes have been 
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generated to date. 
2.2.1.2.2. Transgene expression in neurons from genomic vectors 
Identifying promoter elements capable of directing sustained, long-lasting 
gene expression in neurons from non-replicative genomic HSV-1 vectors has proved 
challenging. Viral promoters such as the cytomegalovirus (CMV) IE promoter or 
HSV-1 IE and E promoters, have been shown to direct strong, but transient gene 
expression, being subject to silencing upon establishment of latency in infected 
neurons.57,58,59   
In neurons the viral genome is silenced with the exception of the latent 
associated transcripts (LAT).60,61 Thus, the LAT locus region escapes the general 
cellular suppression of the activity of HSV-1 promoters during latency, becoming an 
ideal candidate for transgene expression in the context of HSV-1 genomic vectors. 
The most abundant 2-kb LAT is a stable intron 62,63  with one promoter element 
(latency associated promoter 1, LAP1) located 700 bp upstream of the intron64  and a 
second (LAP2) located downstream of LAP1 and just proximal to the LAT intron.65  
Elements of the region active in latency including both LAP1 and LAP2 have been 
confirmed capable of sustaining functional transgene expression even at genomic 
locations outside of the latency locus and for extended times in the central and 
peripheral nervous system.58,65,66,67,68,69,70    
Non-viral promoters have been less well studied in the context of 
nonreplicative genomic vectors although recently, a cellular injury-specific promoter 
(galanin promoter)71 was shown to drive functional transgene expression in the spinal 
cord of mice after viral vector administration by injection into the plantar hind paw. 
Also of interest, the use of inducible promoters such as the Tet-inducible system has 
been studied to control transgene expression in HSV-1 genomic vectors72,73,74 
although their leakiness remains an obstacle.75,76,77   
 
2.3. Friedreich’s ataxia (FRDA) 
2.3.1. Introduction 
Friedreich’s ataxia [FRDA; OMIM229300] is a predominantly 
neurodegenerative disorder named after German physician Nikolaus Friedreich, who 
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first reported the condition and its clinical and pathologic features during the 1860s 
and 1870s.78,79,80,81,82 This autosomal and recessive disease is the most common form 
of hereditary ataxia 83 and is caused by mutations in the frataxin gene (FXN), which 
lead to a partial deficiency of the encoded mitochondrial frataxin protein (FXN).84 
FRDA primarily affects Caucasians and disease incidence is estimated at 2-3:100.000 
in the Western European population with 1 carrier per 100 people.85 Symptoms 
usually appear late in the first decade of life and mainly include progressive gait and 
limb ataxia, sensory loss, dysarthria, dysmetria, dysphagia, muscular weakness, 
visual loss, and hearing deficit.86,87 In addition, patients develop non-neurological 
manifestations such as risk of hyperglycemia, diabetes mellitus and development of 
hypertrophic cardiomyopathy. 83,88 Within 20 years after the first appearance of 
symptoms, affected individuals are confined to a wheelchair and most commonly die 
in early adulthood from the associated heart diseases.89 There is currently no 
treatment for FRDA. 
2.3.2. FRDA pathophysiology  
FRDA is a severe disease affecting peripheral and central nervous systems, 
heart, endocrine pancreas and skeleton. 
2.3.3. Neuropathological features  
Clinical symptoms and neurological examinations 86,87,90,91 indicate that FRDA 
corresponds to a mixed sensory and cerebellar ataxia, which affects the 
proprioceptive pathways in the peripheral nervous system, spinal cord, and nuclei of 
the cerebellum. 
2.3.3.1.1. Peripheral lesions 
Atrophy of the dorsal root ganglia (DRG) is a major hallmark of FRDA with a 
reduction in the overall size of nerve cells and loss of large neurons. As the disease 
progresses, neuronal destruction becomes manifest by satellite cell proliferation 
coupled with the formation of residual nodules, clusters of nuclei from residual 
neurons and a thickened rim of ferritin-positive cells. Both DRG neurons and satellite 
cells exhibit iron dysmetabolism.92,93,94 Where the primary pathological process 
occurs is still uncertain. Neuropathy of peripheral sensory nerves also contributes to 
the disability of FRDA patients. Observations on the sural nerves of FRDA patients 
showed loss of large myelinated fibers and degeneration of large axons in the 
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DRG95,96; this axonopathy has been associated with a dying back mechanism.97,98 
Further studies have recently suggested a critical role of Schwann cells in this 
afferent neuropathy although no clear evidence on the primary involvement of these 
cells exists. 99  
2.3.3.1.2. Spinal cord and brainstem lesions 
An anterograde effect of axonal neuropathy provokes degeneration of the 
posterior column; atrophy is observed in the dorsal spinocerebellar fibers and nerve 
cells of Clarke’s column, where the spinocerebellar tracts originate. In the dorsal 
column, medial, gracile and cuneate nuclei show trans-synaptic degeneration with 
intense gliosis. Although peripheral motor neurons are not affected, atrophy of 
pyramidal Betz cells and corticospinal tracts constitute secondary intrinsic 
lesions.91,98,100   
2.3.3.1.3. Cerebellar lesion 
The main lesions in the brain of FRDA patients are found in the dentate 
nucleus of the deep cerebellar nuclei with progressive and selective atrophy of large 
glutamatergic neurons and proliferation of corticonuclear synaptic terminals, termed 
grumose degeneration.101 Moreover, the dentate nucleus is small and has a high 
concentration of iron that is not properly removed from the affected brain tissue. In 
contrast, Purkinje cell somata and dendrites in the cerebellar cortex remain intact.102   
 
2.3.3.2. Non-neuropathological features 
Heart disease in FRDA evolves independently of the neurological 
manifestations of FRDA and sometimes may precede it.90,103,104 Cardiac dysfunction, 
which develops during the fourth decade of patient lifetime, is present in more than 
90% of the patients and is the most frequent cause of death, most commonly from 
congestive heart failure or arrhythmia.83,89,103 Pathological changes are observed in 
the left ventricle mainly including cellular hypertrophy, diffuse fibrosis, and focal 
myocardial necrosis.102,105,106 Intra-cytoplasmic granular deposits of iron were 
observed in histological studies of necropsic hearts.107   
In FRDA patients, the incidence of diabetes mellitus and glucose intolerance 
is estimated to be around 10% and 30% respectively.86,90 Furthermore, skeletal 
deformities are very common in FRDA patients including pes cavus (hammer toes) 
and kyphoscoliosis (abnormal lateral and posterior curvature of the vertebral 
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column).86,90   
2.3.4. The frataxin gene (FXN) 
The FXN, located at chromosome 9q21.11 [OMIM 606829], is transcribed in 
the centromere-to-telomere direction and has 7 exons spread over 80 kb of genomic 
DNA: the coding exons 1, 2, 3, 4, together with the alternate exons 5a and 5b, and a 
sixth non-coding exon.108   
Factors controlling FXN transcription are not completely understood. Two 
transcription start sites (TSS), designated TSS1 and TSS2, have been identified at 
221 base pairs (bp) and 62 bp upstream of the TSS, respectively. 84 Moreover, two 
transcription factors, the serum response factor (SRF) and transcription factor 
activator protein 2 (TFAP2), have been reported to bind directly to the region 
between TSS1 and TSS2 and regulate FXN expression.109 An early study with 
reporter luciferase constructs in mouse skeletal muscle cells suggested that FXN 
promoter activity is contained within the first 1,255 bp immediately upstream of exon 
1110 although later findings showed that an extended region, comprising 5,577 bp 
upstream of exon 1, indeed contains important regulatory elements essential for 
maximal FXN gene expression.111 This region includes a highly conserved non-
coding region, which allocates a 17 bp sequence (between 4,944 bp and 4,961 bp) 
containing an Oct-1 binding site, and was shown to be sufficient and necessary for 
fully FXN expression.  
The implication of the sequences within intron 1 in regulation of the FXN 
expression has been also reported and mapping of the region immediately upstream 
of GAA repeats (724 bp) identified sequences that enhance FXN promoter activity  
(Figure 5).109,112,113  
 
2.3.4.1. FXN expression  
Three different FXN transcripts were primarily described. Among them, the 
most abundant (FXN isoform I; FXN-I) is composed by exons 1-4 and 5a 
(NM_000144) and encodes for a 210-amino acids protein (NP_000135) (Figure 5).84 
A second minor alternative transcript was described to contain exon 5b in place of 
exon 5a (NM_001161706), sometimes followed by the noncoding exon 6, and to 
encode a shorter protein of 171 amino acids (NP_001155178). A third splice variant 
of FXN was identified to be composed of exons 1–4 and 5a (NM_181425) but differs 
from isoform I by an insertion of 8  bp due to an alternative splice site at the 5′ end of 
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intron 4. The 8  bp insertion generates a frame shift that introduces a stop codon, so 
that this transcript encodes a shorter protein of 196 amino acids (NP_852090).114,115 
These second and third transcripts have not been studied in detail and no functional 
data about these protein isoforms have been reported. The functional significance of 
these three transcripts is still uncertain.  
Recently, two novel FXN transcript variants have been identified encoding 
isoform II (FXN-II) and isoform III (FXN-III) (Figure 5).116 These transcripts differ 
from isoform I in the amino terminal (N-terminal) region encoded by the first exon 
while exons 2-5a are present in all three FXN isoforms. Alternate splicing was shown 
to generate either an intact exon 1, contained in FXN isoform I; exon 1 lacking 141 
nucleotides, contained in a FXN transcript encoding a 164 amino acid protein 
(isoform III); or an exon 1B lacking 18 nucleotides and contained in a FXN transcript 
encoding a protein of 135 amino acids (isoform II). Furthermore, contrary to the 
mitochondrial localization of the canonical isoform I, isoform II exhibits cytoplasmic 
expression in the central nervous system and isoform III, nuclear localization in the 
heart. Further functional analyses have pointed to their implication in the metabolism 
of iron-sulfur (Fe-S) clusters, suggesting a complementary role with isoform I and a 
direct mechanism by which FXN deficiency could cause tissue-specific pathology in 
Friedreich’s ataxia.116   
 
 
 
Figure 5. Schematic representation of the human FXN genomic locus and FXN isoforms 
I, II and III 
a. Schematic (not to scale) representation of the genomic structure of the human FXN locus 
on the long arm of chromosome 9 with centromeric (9qc) to telomeric (9qt) orientation 
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indicated. FXN contains seven exons: exons 1, 2, 3, 4, alternate exons 5a/5b, and a sixth non-
coding exon (gray vertical boxes). Localization of the trinucleotide guanine-adenine-adenine 
repeats (GAA) is shown in intron 1, the expansion of these triplet repeats being identified as 
the major cause of FXN depletion in FRDA. Two transcription start sites TSS1 and TSS2 
(black arrows with arrow heads representing the direction of the transcription) are shown 
located at 221 base pairs (bp) and 62 bp upstream of the translational start site (ATG), 
respectively. Several protein-binding sites (white vertical boxes) known to be important for 
FXN regulation include sites for the octamer binding transcription factor 1 (OCT1), the serum 
response factor (SRF), the transcription factor activator protein 2 (TFAP2) and the early 
growth response protein 3-like factor (EGR3-like).  
b. Schematic representation of three of the FXN transcript variants described. Exons 1-5a 
encode the canonical FXN isoform (FXN-I). Exons 1BΔ18-5a encode the predominantly 
nervous system-expressed FXN isoform (FXN-II). Exons 1Δ141-5a encode the 
predominantly heart-expressed FXN isoform (FXN-III). 
 
 
The FXN gene is considered ubiquitously expressed at a relatively low level 
even in healthy individuals.117,118 Transcript variants and levels of FXN mRNA as 
well as FXN protein show specificity to tissues with high mitochondrial content such 
as the brain, heart, pancreas, skeletal muscle, liver and brown adipose tissue119 a 
distribution which partially correlates with the sites of the disease. The basis of the 
differential sensitivity of tissues to FXN deficiency is not clear but it has been 
suggested that it depends on cell type-specific metabolic pathways, the somatic 
instability of expanded GAA triplet repeats and tissue-specific FXN 
isoforms.116,120,121,122,123,124 Highlighting the importance of FXN in development, mice 
lacking FXN display embryonic lethality early in gestation.125 On the other hand, 
over-expression of FXN was shown to be toxic in cultured fibroblasts and in a 
Drosophila model, thus suggesting the importance of a fine balance in FXN 
regulation.126,127   
2.3.5. FRDA mutations: GAA Repeat Expansions 
The FXN gene is unique in the human genome in that normal alleles contain 
up to 66 uninterrupted guanine-adenine-adenine (GAA) trinucleotide repeats within 
intron 1. Approximately 98% of individuals suffering from FRDA have between 67 
to over 1300 GAA repeats in both FXN alleles, with a minority of 2% of the patients 
having expansions in only one allele and a point mutation in the coding region of the 
other.84 This repetitive sequence in intron 1 plays an important regulatory role in 
FXN, with the number of GAA repeats higher than the pathological threshold 
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resulting in impaired FXN transcription.84 Relative to healthy individuals, FXN is 
expressed in FRDA patients at 5-30% of normal levels.115,120 Furthermore, an inverse 
correlation has been described between the size of the expanded GAA sequence and 
FXN transcript levels, the amount of residual FXN produced and the age of onset of 
FRDA symptoms.128   
 
2.3.5.1. Effect of the GAA repeat expansion on FXN expression 
Although there is still some debate about the exact cause of FXN depletion in 
FRDA, some mechanisms have been proposed to contribute. These include GAA 
repeat-dependent structural changes in the DNA, which physically block the 
transcriptional machinery129,130,131; and epigenetic modifications, such as higher 
levels of DNA methylation132,133, heterochoromatinization and altered histone 
modifications in the intronic region surrounding the expanded repeats. 112,134,135,136   
Since the size of the triplet expansion accounts only for 50% of the variability 
in the age of onset for FRDA 128 other factors have been proposed to impact on the 
disease including toxic RNAs, repeat-associated proteins, aberrant splicing, and 
altered expression of FXN isoforms.  
2.3.6. Frataxin protein (FXN) 
FXN is a predominantly mitochondrial and highly conserved protein with 
homologs present in gram-negative bacteria, yeast, Caenorhabditis elegans and 
mammals.137,138,139,140   
 
2.3.6.1. FXN structure and processing  
The human FXN gene encodes a 210 amino acids poly-peptide (23 kDa), the 
precursor form of FXN. After translation of this nuclear gene product in cytoplasmic 
ribosomes, an N-terminal targeting signal encoded by the first 20 amino acids 120 
directs transport of the precursor protein into the mitochondria 139,141 to undergo two-
step proteolytic processing, mediated by the mitochondrial processing peptidase 
(MPP).142,143 MPP first cleaves the precursor form to remove the 20 N-terminal 
residues, containing the mitochondrial signal peptide. This is followed by the 
generation of an intermediate form of 19 kDa cleaved between G41 and L42 
(residues 42–210), which is then converted into a mature soluble form found within 
the mitochondrial matrix.143  
Identification of the site involved in the second step of processing to generate 
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the mature form remains a controversy. In vivo experiments have established that a 
FXN form termed m81-FXN (14.3 kDa) is the normal mitochondrial mature form in 
living cells and the most abundant species both in normal individuals and in FRDA 
patients. However, two other mature forms termed m56-FXN (17.2 kDa) and m78-
FXN (14.7 kDa) can be produced in vivo when normal processing is impaired or 
when processing is carried out in vitro although the physiological relevance is not 
clear.143,144,145   
 
2.3.6.2. FXN function 
A clear essential cellular function of the FXN protein is still not fully 
established but it has been generally accepted to be a multi-functional protein with a 
major role in the regulation of cellular iron homeostasis. FXN has been described as a 
metallochaperone that can bind iron to supply iron-dependent metalloenzymes such 
as the Fe-S cluster protein aconitase 146; the penultimate protein in heme biosynthesis, 
ferrochelatase147, and complex II of the respiratory chain, succinate dehydrogenase.148 
FXN also binds the cysteine desulfurase Nfs1 and scaffold protein Isu, which are 
components of the Fe-S cluster assembly complex.149   
Mitochondria are present in every cell type, but are especially important in the 
nervous system. This organelle is essential for cellular biochemistry and ATP 
generation as well as being a well-known location for dynamic electron transport and 
redox chemistry. Furthermore heme and Fe-S cluster biosynthesis are the two major 
iron-related metabolic processes in the mitochondrion for delivery, storage and usage 
of iron. Therefore, FXN has a direct impact on mitochondrial function and the 
respiratory chain.119,148  
2.3.7. FRDA molecular pathology  
The clinical and pathological phenotype of FRDA has been widely accepted 
to be caused by decreased levels of FXN which leads to several biochemical 
imbalances such as impaired Fe–S cluster synthesis, resulting in the dysfunction of 
respiratory chain complexes and aconitase, mitochondrial iron overload coupled to 
cellular iron deregulation and oxidative stress hypersensitivity.121,150,151,152,153,154 
However, the primary dysfunction in FRDA pathogenesis is still uncertain and 
affected pathways and functions show a distinct pattern in different organs and 
tissues. 
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2.3.8. Therapeutic approaches 
Currently, no therapy has proven effective in treating FRDA or slowing its 
progression; however, numerous approaches have been trialed and others are in 
various phases of development and testing.155 These approaches can be classified 
based on two criteria, the nature of the treatment, divided into drug-based therapies 
and gene therapies; and the therapeutic target, divided into therapies against 
pathogenic cascades downstream of FXN deficiency and therapies to increase FXN 
expression. 
 
2.3.8.1. Pharmacological therapies  
Pharmacological compounds include: 1) antioxidant compounds such 
ascoenzyme Q, its synthetic analog idebenone, deuterated polyunsaturated fatty acids 
(D-PUFAs), and resveratrol; 2) iron-chelating compounds like deferiprone; 3) 
epigenetic modifying compounds like benzamide histone deacetylase inhibitors 
orinterferon gamma; 4) FXN stabilizers and enhancers including erythropoietin and 
ubiquitin; and 5) neurotrophic factors such as insulin-like growth factor-1.156 Several 
pharmacological agents have shown promising results in animal and cellular models 
but to date none have revealed conclusive and definitive therapeutic benefits in 
clinical trials. 
 
2.3.8.2. Gene Therapy 
Gene therapy of monogenic diseases resulting from a loss of function of an 
essential protein such as FRDA, can be approached directly by the introduction of a 
transgene into target cells to induce or express viable levels of the missing protein. 
2.3.8.2.1. Non-viral delivery systems 
Several technologies for activation of the inhibited FXN gene are currently 
emerging and mainly include: transcription activator-like effector protein (TALE) 
engineered to bind to the FXN promoter 157 and fused to a transcription activation 
domain (VP64); zinc finger nuclease-mediated approaches to excise the expanded 
GAA repeat region from the FXN gene158; and anti-GAA duplex RNAs or single-
stranded locked nucleic acids which interfere with R-loop formed between the 
expanded repeat RNA and complementary genomic DNA.159 Finally, in vivo 
intrathecal delivery into the DRG of FXN mRNA encapsulated in lipid particles was 
recently demonstrated. 
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2.3.8.2.2. Viral delivery systems   
In early studies, expression of human FXN (hFXN) complementing DNA 
(cDNA) coupled to the cytomegalovirus promoter (CMV) and cloned into both a 
lentiviral vector (LV) and an adeno-associated viral vector type-2 (AAV2), was able 
to partially reverse the increased sensitivity to oxidative stress of fibroblasts derived 
from FRDA patients.126 However, total rescue to the normal phenotype was not 
achieved and it was postulated by the authors that this may be because 
overexpression of FXN in cultured primary fibroblasts is toxic.  
More recent studies with AAV vectors have reported encouraging results for 
the cardiac symptoms of FRDA.160 In these studies, intravenous injection of AAV 
vectors of serotype sh10 (cardiotropic serotype) expressing the hFXN cDNA driven 
by the CAG promoter was shown to prevent and reverse severe cardiomyopathy in a 
mouse model with complete FXN deletion in cardiac and skeletal muscle (The CAG 
promoter consists of the enhancer from the cytomegalovirus immediate-early gene, 
the promoter, splice donor and intron from the chicken β-actin gene, and the splice 
acceptor from the rabbit β-globin gene). Treated asymptomatic mice remained 
indistinguishable from WT mice at 35 weeks of age. Moreover, recovery of 7 week 
untreated mice with advanced cardiac insufficiency showed a cardiac phenotype that 
correlated with strong expression and normal mitochondrial localization of hFXN in 
the heart at 1 week to 22 weeks after treatment. However, the development of severe 
peripheral striated muscle atrophy and kyphosis, attributed to a low level of hFXN 
transgene expression in skeletal muscle of the mouse model, led to the death of 
several of these mice. Notably, transgene expression was robust not only in heart, but 
also in the liver of treated mice, although no adverse effects were reported from this 
FXN overexpression. 
In agreement with these results, another group has also demonstrated that 
intraperitoneal injection in a FRDA mouse model of an AAV vector of serotype 9 
(also cardiotropic serotype) expressing the hFXN cDNA, increased life expectancy up 
to threefold.161 In this mouse model with complete ablation of the mouse FXN gene in 
the heart and a partial ablation in the muscle, liver, kidney, and brain, robust 
expression of hFXN was detected in the heart, liver and skeletal muscle. In the brain 
however, hFXN was detected at much lower levels and only with the highest viral 
dose assayed. Injected mice developed nervous pathological symptoms, which were 
attributed to insufficient expression of FXN in the brain of the mice during early 
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embryogenesis. 
A proof-of-concept study using helper-dependent HSV-1 amplicon vectors 
showed that FXN cDNA expression driven by the HSV-1 IE4/5 promoter was able to 
reverse neurological defects to restore motor coordination in a localized FRDA 
mouse model generated and treated by stereotaxic injection in the brainstem.162  
Despite these encouraging results the duration of the effect was transient. As this 
transience of transgene expression was mainly attributed to the fact that viral 
immediate-early promoters were used, subsequent studies took advantage of the large 
packaging capacity of amplicon vectors to deliver the entire human FRDA genomic 
locus, thus maintaining the native promoter, enhancer, and silencer elements, similar 
to that of the native chromosomal gene. 163 FRDA patient fibroblasts transduced with 
this FXN vector showed a physiological level of FXN expression and functional 
restoration of the WT cellular phenotype in response to oxidative stress.  
In a second study with these viral vectors encoding the entire FXN locus, 
long-term persistence of hFXN expression in the brain was observed after stereotaxic 
injection into the adult mouse cerebellum.164 Interestingly, transgene expression 
driven by the FXN locus was shown to persist for at least 75 days at approximately 
the same levels, while injection of a control amplicon vector carrying a GFP reporter 
gene driven by the HSV-1 IE4/5 promoter showed transient transgene expression 
which decreased down to 20–50% during the same period. Moreover, delivery of the 
135 kb hFXN genomic DNA locus by amplicon vectors was recently shown to give 
rise to the different frataxin isoforms both in vitro and in vivo165, supporting the 
potential use of HSV-1 vectors containing the human FXN genomic locus for FRDA 
therapeutic applications.  
Results from these studies indicate that increasing FXN levels can improve 
phenotype and ultimately clinical outcome, encouraging further studies testing the 
corrective potential of these gene therapies for FRDA. Finally, promising data in 
FRDA animal models has also been obtained using a number of FRDA gene therapy 
strategies to deliver other transgenes, such as HSV-1 amplicon vector delivery of the 
gene encoding brain-derived neurotropic factor (BDNF)166 or AAV9 vector delivery 
of the TALEs proteins.167  
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3. OBJECTIVES 
 
The overall aim of this dissertation was to test the hypothesis that a novel 
nonreplicative genomic HSV-1 vector is able to deliver and maintain the expression 
of a human frataxin (FXN) transgene in the dorsal root ganglia to develop a gene 
therapy for the neurological symptoms of Friedreich’s ataxia (FRDA). 
A recombinant nonreplicative genomic HSV-1 vector used in a recent clinical 
trial demonstrated an excellent safety profile even at high doses.53 However, the 
transgene capacity of this vector is limited to approximately 10 kb which restricts its 
use for delivery of large sequences such as the FXN genomic locus previously used 
by our group in preclinical experiments. To test if an increased transgene capacity can 
be achieved without compromising scalable high-titer vector production, we deleted 
further HSV-1 genome sequences and analysed the in vitro effects of these deletions 
on the growth capacity of the resulting vectors. 
Since the human FXN genomic locus fragment we previously used may be 
larger than necessary for gene therapy, we generated a construct comprising the 5 kb 
promoter and the FXN cDNA with the inclusion of intron 1.  To test in vitro if this 
reduced genomic FXN transgene retains the regulatory elements necessary to preserve 
the physiological neuronal regulation, we analysed the FXN alternative splicing as 
well as the FXN protein expression in a neuronal cell line. 
The trimmed human FXN transgene was coupled to the new high capacity 
non-replicative genomic HSV-1 vector. To test if the resulting recombinant mutant 
preserves the main characteristics of both the transgene and the vector, we first 
analysed in vitro the transgene expression in the context of the genomic vector in 
fetal rat dorsal root ganglion neurons. Finally, we examined the transgene delivery 
and expression in the dorsal root ganglia following inoculation of rat footpads.  
 
My approach consisted of the following specific aims: 
 
I. To generate a nonreplicative genomic HSV-1 vector with a 23 kb genome 
deletion while retaining its growth capacity. 
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II. To generate a reduced version of the human FXN genomic locus while 
maintaining the elements necessary to undergo physiological neuronal 
regulation. 
 
III. To determine if the generated nonreplicative genomic HSV-1 vector carrying 
the reduced version of the human FXN genomic locus is able to deliver and 
sustain the human FXN transgene expression in dorsal root ganglia after rat 
footpad inoculation. 
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4. MATERIALS 
4.1. Reagents 
Dulbecco's Modified Eagle Medium (DMEM), Neurobasal Medium, 
Leibovitz’s L-15 Medium, Opti-MEM, TrypLE and Trypsin-EDTA were purchased 
from Gibco/Life Technologies, Paisley, UK. Antibiotics used in cell cultures and 
bacterial cultures (penicillin G, streptomycin sulfate, zeocin, ampicillin, kanamycin, 
tetracycline, chloramphenicol, G418), L-arabinose, doxycycline hyclate (Dox), nerve 
growth factor (NGF), fluoro-2deoxy-uridine (FDU), uridine, poly-D-lysine, Ketamine 
and Xylazine were purchased from Sigma-Aldrich (St. Louis, MO). B-27, Glutamax 
I, Albumax I supplements and laminin were obtained from Gibco/Life Technologies 
(Grand Island, NY). Fetal bovine serum (FBS, product number F7524) and 
Isopropylβ-D-1-thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal) were from Sigma-Aldrich (St. Louis, MO) whereas 
TRIzol, Lipofectamine-LTX and Plus reagents were purchased from Life 
Technologies (Carlsbad, CA). 
4.2. Bacterial strains 
 
Strain  Genotype  Source/ Ref  
DH10B  F– mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80dlacZΔM15 
ΔlacX74 endA1 recA1 
deoR Δ(ara,leu)7697 
araD139 galU galK nupG 
rpsL λ-  
(Durfee et al, 2008; 
Grant et al,  
1990)168,169   
DH5α  F– Φ80lacZΔM15 
Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ–thi-
1 gyrA96 relA1  
(Taylor et al,  
1993)170  
PIR1  F– Δlac169 rpoS(Am) Life Technologies 
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robA1 creC510 hsdR514 
endA recA1 
uidA(ΔMluI)::pir-116  
 
(Carlsbad, CA), 
catalogue number- 
C1010-10  
 
4.3. Cell lines 
 
Cell line  Origin  Culture Media  Source/Ref of the 
plasmid used for 
construction of 
stable cell lines  
Vero  African green 
monkey kidney 
epithelial cell line 
F10 medium consisting of 
DMEM supplemented with 
10% FBS, 100U/ml 
penicillin G and 100 µg/ml 
of streptomycin sulfate 
ATCC* CRL 
1586 (Earley EM 
et al, 1988)171  
2-2 Vero cell line 
expressing the 
ICP27 gene  
F10 medium supplemented 
with G418 (500µg/ml)  
(Smith et al, 
1991)172  
E5  Vero cell line 
expressing the 
ICP4 gene 
F10 medium supplemented 
with G418 (500µg/ml) 
(DeLucca & 
Shaffer  
1987)54  
7b Vero cell line 
expressing both the 
ICP27 and the 
ICP4 gene 
F10 medium supplemented 
with G418 (500µg/ml) 
 
(Krisky et al, 
1998)51  
 
Neuro-2a Mouse 
neuroblastoma cell 
line 
F10 medium 
 
ATCC* CCL 131 
(Klebe and 
Ruddle, 1969)173  
HEK-293 Human embryonic 
kidney cell line 
F10 medium 
 
ATCC* CRL 
1573 (Graham et 
al, 1977)174  
Materials 
 36 
SH-SY5Y Human  
bone marrow 
neuroblastoma cell 
line 
F10 medium 
 
ATCC* CRL 
2266 (Biedler et 
al, 1978)175  
*ATCC is the registered trademark of the American Type Culture Collection. 
4.4. Plasmids 
 
Plasmid  Selection marker  Source / Ref  
FXN-WT BAC  
 
Choramphenicol 
 
(Gomez-Sebastian 2007)163  
 
pBluescriptKSII(+)  Ampicillin  (Alting-Mees & Short, 1989)176  
 
pCTP-T  Tetracycline   (Saeki et al, 2001)177  
 
pDRIVE-CAG  Zeocin  Invivogen, San Diego, CA  
 
pGEMT Easy  Ampicillin  Promega, A1360  
 
pGZI27Spe Ampicillin 
Zeocin 
Polymerase chain reaction 
(PCR) amplified Sh ble gene 
using primers PACSPE and 
I27DZ cloned into pGEMT Easy 
vector  
 
pHG Ampicillin 
 
(Saeki et al, 2001)177  
 
pLCG Ampicillin 
 
EcoRI/BgIII pUcCombi_CMV 
blunted with Klenow and 
religated into BamHI/NruI 
pLOsG 
 
pLCG-ZEO Zeocin PCR amplified Sh ble gene 
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using primers PACSPE and R7 
cloned into pLCG 
 
pLOsG Ampicillin SalI/SpeI pHG blunted with 
Klenow and religated in 
presence of dNTPs  
 
pLVfrat 
 
Ampicillin (Fleming et al, 2005)126  
pSK+Kana-RPSL  Ampicillin,  
Kanamycin 
Addgene, Cambridge MA, 
(Wang et al, 2009)178  
pSKC481.9 Ampicillin XhoI/EcoRI Cos48 ligated into 
pBluescriptSK  
 
pSKOrisZ Zeocin NotI/SpeI pGZI27Spe cloned 
into NotI/SpeI pSKC481.9 
 
pUcCombi_CMV Kanamycin 
 
(Schultze N et al, 1996)179  
 
4.5. Virus 
The parental virus strain used in this study was strain F of HSV-1.180 The viral 
genome of strain F cloned in a bacterial artificial chromosome (BAC) plasmid181 was 
used for the construction of all the mutants. 
4.6. Oligonucleotides 
 
PCR: Red/ET recombination 
 
Primer Sense  Sequence (5’-3’) 
FL5111K Backward  
 
TGGAATGCAATTTGATACATCACCTTAAT 
ATTAATATAGATTAAATTCATATAACTTC 
GTATAATGTATACTATACGAAGTTATCAG 
Materials 
 38 
AAGAACTCGTCAAGAAGGC      loxP511 
I43P Backward GCCACAGGTGAAACCAACAGAGCACGGCGC 
ACTCCGCACGTCACACGTCATTAATTAATCA 
GAAGAACTCGTCAAGAAGGCGAT 
I45P Forward TCTAGAAAGCATCGACCGGTCCGCGCTAGT 
TCCGCGTCGACGGCGGGGGTCGTCGGTTAA 
TTAAGTTTTATGGACAGCAAGCGAACCGG 
I4OS5 Forward TCTAGAGTCTGCGGGCGTCGGTCGCGCCGG 
GCCTTTATGTGCGCCGGAGAGACCCGTTAA 
TTAAGTTTTATGGACAGCAAGCGAACCGG 
I27DZ Forward CTCGAGACGCGTCATATGCAAATGAAAATC 
GGTCCCCCGAGGCCACGTGTAGCCTGAATT 
AAATTTTTCAAAAGTAGTTGAC 
I27DA Forward  
 
ACGCGTCATATGCAAATGAAAATCGGTCCC 
CCGAGGCCACGTGTAGCCTGGCACTTTTCG 
GGGAAATGTG 
IRTGA Backward  CGGCGGGCGGGACCGGGGGCCCGGGGACG 
GCCAACGGGCGCGCGGGGCTCCAGTTACCA 
ATGCTTAATCAG 
IRTGZ Backward CGGCGGGCGGGACCGGGGGCCCGGGGACG 
GCCAACGGGCGCGCGGGGCTCCCTTTTCTG 
AAACTCAATTCTTATC 
PACSPE Backward  
 
GACTAGTTAATTAAGTTGAAAAAAGGGGCC  
 
T7TN5 Forward ATATTGCTCTAATAAATTTGCGGCCGCTAAT 
ACGACTCACTATAGGGAGAGTTTTATGGACA 
GCAAGCGAACCGG 
US3Z Backward CTCGAGAAATGTCGGCCATCCAGAAAACGT 
CCCGGAGGACCACAGTGGCTTCCCCCCGGA 
TCCTATCGGTACCTTTTCTGAAACTCAATTC 
TTATC 
Z143P Backward CGTCAAATTAAATTTTTCAAAAGTAGTTGAC 
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PCR: Red/ET recombination 
 
Primer Sense  Sequence (5’-3’) 
FL5111K Backward  
 
TGGAATGCAATTTGATACATCACCTTAAT 
ATTAATATAGATTAAATTCATATAACTTC 
GTATAATGTATACTATACGAAGTTATCAG 
AAGAACTCGTCAAGAAGGC      loxP511 
I43P Backward GCCACAGGTGAAACCAACAGAGCACGGCGC 
ACTCCGCACGTCACACGTCATTAATTAATCA 
GAAGAACTCGTCAAGAAGGCGAT 
I45P Forward TCTAGAAAGCATCGACCGGTCCGCG 
CTAGTTCCGCGTCGACGGCGGGGGT 
CGTCGGTTAATTAAGTTTTATGGACA 
GCAAGCGAACCGG 
I27DZ Forward CTCGAGACGCGTCATATGCAAATGAAAATC 
GGTCCCCCGAGGCCACGTGTAGCCTGAATT 
AAATTTTTCAAAAGTAGTTGAC 
I27DA Forward  
 
ACGCGTCATATGCAAATGAAAATCGG 
TCCCCCGAGGCCACGTGTAGCCTGGC 
ACTTTTCGGGGAAATGTG 
IRTGA Backward  CGGCGGGCGGGACCGGGGGCCCGGGGAC 
GGCCAACGGGCGCGCGGGGCTCCAGTTAC 
CAATGCTTAATCAG 
IRTGZ Backward CGGCGGGCGGGACCGGGGGCCCGGGGAC 
GGCCAACGGGCGCGCGGGGCTCCCTTTTC 
TGAAACTCAATTCTTATC 
PACSPE Backward  
 
GACTAGTTAATTAAGTTGAAAAAAGGGGCC  
 
T7TN5 Forward ATATTGCTCTAATAAATTTGCGGCCGCTA 
ATACGACTCACTATAGGGAGAGTTTTATG 
GACAGCAAGCGAACCGG 
US3Z Backward CTCGAGAAATGTCGGCCATCCAGAAAACGT 
CCCGGAGGACCACAGTGGCTTCCCCCCGGA 
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TCCTATCGGTACCTTTTCTGAAACTCAATTC 
TTATC 
Z143P Backward CGTCAAATTAAATTTTTCAAAAGTAGTTGAC 
 
PCR: plasmid construction 
 
Target Primer Sequence (5’-3’) Plasmid 
generated  
FXN 
cDNA 
ex2-5a 
R3 
 
R4 
GTACTGCAGTTCGAACCAACGTGGCC
TC 
GGCCTATTCCGGAAAAGATGCTGGA
AGCGGAGCTACTAACTTCAGCCTG
CTGAAGCAGGCTGGAGACGTGGAG
GAGAACCCTGGACCCATGGACGTTA
A            PTV1 2A 
pF2A 
KanR R5 
 
 
R6 
ACGTTAATTAATAACTTCGTATAATG
TATGCTATACGAAGTTATGTTTTATG
GACAGCAAGCGAACCGG 
GCCTTCTTGACGAGTTCTTCTGACATC
AAAAAAATTGTAAAACAAGCCACAG
TTCTGACTTTTACGACTGCACGTCGA
CTCA 
pF2ALRK 
ZeoR R7 
 
 
 
PACSPE 
GCGGCCGCGGGAATTCGATTCTCGAG
TTATAACCCCGGGGGTCATTCCCAAC
GATCACATGCAATCTAACTGGCTCAA
TTAAATTTTTCAAAAGTAGTTGAC 
GACTAGTTAATTAAGTTGAAAAAAGG
GGCC 
pLCG_Zeo 
ZeoR I27DZ 
 
 
 
CTCGAGACGCGTCATATGCAAATGAA
AATCGGTCCCCCGAGGCCACGTGTAG
CCTGAATTAAATTTTTCAAAAGTAGT
TGAC 
pGEMTeasyZ 
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PACSPE GACTAGTTAATTAAGTTGAAAAAAGG
GGCC 
PCR: neuro-2a cells 
 
Target Primer Sequence (5’-3’) Annealing 
temperature  
hFXN  
isoform I 
P1 
P2 
CGGAGCAGCATGTGGACTCT 
TGGTTGAGGCCACGTTGGTTC 
57ºC 
hFXN  
isoform II 
P3 
P4 
GACATTTTGTCCTGCGGTGCGACT 
GGCTTGTCTGCAAGGTCTTC 
60ºC 
GFP P5 
P6 
TTTGCACGGGAGGAACGTCC 
AAGTCGTGCTGCTTCATGTG 
57ºC 
β-Actin P7 
 
P8 
 
CCTGAACCCTAAGGCCAACCGTGAA
AAGATGAC 
GGCATAGAGGTCTTTACGGATGTCA
ACGTC 
60ºC 
PCR: cultured DRG neurons 
 
Target Primer Sequence (5’-3’) Annealing 
temperature  
LacZ P9 
P10 
TACCTGTTCCGTCATAGCGATAACG 
AGCGTCACACTGAGGTTTTCC 
57ºC 
GFP P5 
P6 
TTTGCACGGGAGGAACGTCC 
AAGTCGTGCTGCTTCATGTG 
57ºC 
GAPDH P11 
P12 
CGGCCGAGGGCCCACTAAAG 
GAGCAATGCCAGCCCCAGCA 
60ºC 
PCR: L4-6 rat DRG  
 
Target Primer Sequence (5’-3’) Annealing 
temperature 
hFXN P13 
P14 
CCGCCGCGCAAGTTCGAACC 
CCACTGGATGGAGAAGATAG 
57ºC 
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GAPDH P15 
P16 
GCCAAGGCTGTGGGCAAGGT 
GGCAGGTTTCTCCAGGCGGC 
60ºC 
qRT-PCR: cultured DRG neurons 
 
Target Primer Sequence (5’-3’) Annealing 
temperature 
LacZ P17 
P18 
ATCTCTATCGTGCGGTGGTT 
GATGATGCTCGTGACGGTTA 
60ºC 
GFP P19 
P20 
AAGAAGATGGTGCGCTCCTG 
GCTACCCCGACCACATGAAG 
60ºC 
GAPDH P15 
P16 
GCCAAGGCTGTGGGCAAGGT 
GGCAGGTTTCTCCAGGCGGC 
60ºC 
 
Secuencing 
 
Primer Sense Sequence (5’-3’) 
3’TN5pr Backward TTCCCAACCTTACCAGAGGGCG 
AMP3’OUT Forward CCCGTATCGTAGTTATCTAC  
GK3P Forward CTGTTCCATCATCCTCTCGGGCATC 
ICP225’OUT Backward CGCTTTTACACAAGGCGCAA 
LACZ3OUT Forward TCGCTACCATTACCAGTTGG 
MARIZEO Forward CACTTTGTGGCAGAGGAGCAGGA  
prG Backward GGCTTGTCTGCAAGGTCTTC 
RPrev Backward GGAGTGGTAGTATATACACGAG  
SEQK5 Forward CGTGCTTTACGGTATCGCCG  
SU1LOXHSV Forward TGCAGGAATTCGATATCAAG  
SU2LOXHSVUL4 Backward CGCCCTGGAATACGCAGACA  
Z5PRV Backward TGTGAGCACTGGGACAGCAC 
 
4.7. Antibodies 
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Primary  Secondary  Dilution/ Assay  
Anti-Frataxin mouse 
monoclonal (Abcam,  
Cambridge, UK) 
anti-mouse IgG peroxidase 
conjugate (1:2000) (Sigma-
Aldrich, St. Louis, MO). 
 
1:1000 
Western 
Anti-β-Galactosidase 
mouse monoclonal 
(Promega, Madison, WI) 
anti-mouse IgG peroxidase 
conjugate (1:2000) (Sigma-
Aldrich, St. Louis, MO)  
 
1:2000 
Western 
Anti-GFP rabbit 
polyclonal (Chemicon, 
Temecula, CA) 
anti-rabbit IgG peroxidase 
conjugate (1:2000) (Sigma-
Aldrich, St. Louis, MO)  
 
1:1000 
Western 
Anti-β-Actin mouse 
monoclonal (Sigma-
Aldrich, St. Louis, MO) 
anti-mouse IgG peroxidase 
conjugate (1:2000) (Sigma-
Aldrich, St. Louis, MO)  
 
1:2000  
Western  
Anti-HSV-1 rabbit 
polyclonal (Dako 
Cytomation, Glostrup, 
Denmark)  
anti-rabbit IgG peroxidase 
conjugate (1:2000) (Sigma-
Aldrich, St. Louis, MO)  
1:1000  
Immunosubstrate 
staining  
 
4.8. Buffers and solutions 
 
1X Tris-acetate (TAE)  40mM Tris, 20mM acetic acid, and 1mM 
EDTA  
 
1X Phosphate buffered saline (PBS)  137mM NaCl, 2.7mM KCl, 10mM 
Na2HPO4 and 1.8mM KH2PO4  
 
1X Electrophoresis buffer  25 mM Tris, 192 mM glycine, 0.1% SDS  
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1X Transfer buffer  25 mM Tris, 192 mM glycine, 20% 
methanol, 0.1% SDS 
 
1X Phosphate Buffered Saline with 
Tween 20 (PBST) 
 
1XPBS, 0.05% Tween 20  
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5. METHODS 
5.1. MOLECULAR BIOLOGY TECHNIQUES 
5.1.1. Agarose gel electrophoresis  
1% (percent weight/volume (w/v)) gels were prepared using 1X Tris acetate 
EDTA (TAE) buffer (see section 4.8) and adding ethidium bromide staining solution 
to a final concentration of 0.5 µg/ml (Sigma-Aldrich, St. Louis, MO). Blue/Orange 
6X loading dye (Promega, Madison, WI) was added to a final concentration of 1X to 
each DNA sample prior to loading. For DNA size markers a 100 bp DNA ladder 
(NEB) was used in all gels. The bands were visualized using a PC-based image 
analysis system (ChemiDoc XRS System; Bio-Rad, Hercules, CA). 
5.1.2. Restriction enzyme digestions  
Restriction enzyme digests were performed on plasmid DNA in a total volume 
of 30 µl containing 0.5 µg (plasmid) - 2µg (BAC) DNA, 0.5 – 1µl restriction enzyme 
(10 U/µl), 3µl of the corresponding restriction buffer (10X) and double-distilled 
water. The digests were incubated at 37°C from 1 hour to overnight followed by 
electrophoresis on a 1% agarose gel as described in the previous section 5.1.1. 
5.1.3. DNA extraction and purification from gel bands – Phenol/Ethanol method 
To perform standard DNA extraction and purification from gel bands, a small 
hole was made in the bottom of a 0.5 ml microcentrifuge tube and covered with glass 
wool. The agarose slice containing the DNA band of interest was excised using a 
clean scalpel and placed in the microcentrifuge tube on top of the glass wool. The 
tube containing the gel slice was then placed inside a larger (1.5 ml) microcentrifuge 
tube and centrifuged at 11,000 xg for 1 minute. The liquid obtained in the 1.5 ml 
microcentrifuge tube was collected and added to buffered phenol (Phenol solution 
equilibrated with 10mM Tris HCl, pH 8.0 and 1mM EDTA; Sigma-Aldrich, St. 
Louis, MO) at a ratio of 1:1. The liquids were mixed by vortexing and then 
centrifuged at 11,000 xg for 5 minutes to separate the aqueous and organic phases. 
The upper aqueous phase was collected with a pipette, transferred to a new 1.5 ml 
microcentrifuge tube and DNA precipitated by the addition of 0.1 volumes 3M 
sodium acetate (pH 5.4), 3 volumes ethanol and 10 ng/µl of glycogen carrier. The 
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tube was incubated at -20ºC for 1 hour and then centrifuged at 11,000 xg for 30 
minutes at 4°C. The DNA pellet obtained was washed once with 1 ml of 70% 
ethanol, air dried and dissolved in double-distilled water. The concentration of 
purified DNA was measured at 260 nm using a nanodrop spectrophotometer (ND-
1000) and the relationship that an absorbance reading at 260 nm of 1.0 for a 1 cm 
path length of a solution of double-stranded DNA corresponds to a concentration of 
50 µg/ml.   
5.1.4. DNA extraction and purification from gel bands – Gel extraction kit  
In order to sequence DNA PCR products, the DNA band of interest was 
excised and purified from agarose gel using a gel extraction kit according to the 
guidelines provided by the manufacturer (Quiagen, Valencia, CA). The concentration 
of purified DNA was measured using a nanodrop spectrophotometer (ND-1000). 
5.1.5. DNA ligation reactions 
For each ligation reaction, 50 ng of vector DNA was mixed at a 1:3 molar 
ratio with the insert DNA along with 0.2 µl (5 U/µl) of T4 DNA ligase (Thermo 
Scientific, Carlsbad, CA) in ligase buffer (Thermo Scientific, Carlsbad, CA) in a final 
volume of 10 µl. A control sample with no insert DNA was always included to reveal 
uncut or religated vector. Reaction mixtures were incubated overnight at 16°C or 1 
hour at room temperature. 
5.1.6. Total RNA extraction - TRIzol method  
Total RNA was extracted from isolated rat dorsal root ganglia (DRG) of 
lumbar levels 4-6 (L4-6) 7 days or 30 days after viral injection using TRIzol 
following supplier guidelines (Invitrogen, Carlsbad, CA). DRG were resuspended and 
disrupted in 1 ml of TRIzol with a homogenizer (Micro homogenizer, OMNI-Inc, 
Kennesaw, GA). Homogenized samples were then incubated for 10 minutes at room 
temperature and 0.2 ml of chloroform per 1ml of TRIzol added, followed by shaking 
of samples for 15 seconds. The mixture was incubated for a further 3 minutes at room 
temperature and then centrifuged at 12,000 xg for 15 minutes at 4°C to separate the 3 
layers: a lower red phenol-chloroform phase, an interphase, and a colorless upper 
aqueous phase. The upper aqueous phase was collected carefully in a new 
microcentrifuge tube and 0.5 ml isopropanol was added. The mixture was incubated 
at room temperature for 10 minutes and then centrifuged at 12,000 xg for 10 minutes 
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at 4°C to yield an RNA pellet. The pellet was washed with 75% ethanol and then 
dried at room temperature to ensure that no contaminating ethanol remained. 
Ribonuclease-free water was added (10-20 µl, depending on the size of the RNA 
pellet).  
5.1.7. Total RNA extraction - RNeasy Plus kit (Qiagen) 
Total RNA from cultured cells was extracted 48 hours after transfection or 
infection using RNeasy plus kit (Qiagen, Valencia, CA) according to the 
manufacturer´s instructions. 
5.1.8. Complementary DNA (cDNA) synthesis  
First strand complementing DNA (cDNA) was synthesized from extracted 
total RNA by reverse transcription polymerase chain reaction (RT-PCR) using the 
Superscript III first-strand synthesis system following the supplier’s instructions 
(Invitrogen, Carlsbarg, CA) and then used as template for a second amplification step 
by PCR or real-time PCR (qPCR) 
5.1.9. Polymerase chain reaction (PCR)  
All primers used for PCR are listed in section 4.6. PCR amplification of 
plasmid DNA or cDNA derived from total RNA extracted from Neuro-2a cells was 
performed using 1 µl (0.1 ng) or 2 µl of template DNA respectively, added to a PCR 
mix containing 5 µl 5X GoTaq flexi buffer, 2.4 µl 25 mM magnesium chloride 
(MgCl2), 0.5 µl 10 mM dNTPs mixture, 0.5 µl of each 5 mM primer and 0.2 µl 
GoTaq DNA polymerase (1 U) (Promega, Madison, WI). The volume was made up 
to 25 µl using double-distilled water. The PCR mixture was incubated in an 
automated thermocycler running a three step amplification protocol: an initial 
denaturing step at 95°C for 5 min followed by 30 cycles (of 95°C for 30 seconds, 55-
65°C for 30 seconds, 72°C for 0.5-1 minutes) and a final extension cycle at 72ºC for 
5 minutes. PCR amplification of FXN isoform II in transfected Neuro-2a cells was 
performed using 40 cycles for increased sensitivity.  
PCR amplification of cDNA derived from total RNA extracted from cultured 
DRG neurons or from L4-6 rat DRG was carried out using 1.5 µl or 0.6 µl of cDNA 
respectively, in 25 µl PCR reactions. Template DNA was added to 2.5 µl 10X buffer, 
0.75 µl 50 mM MgCl2, 0.5 µl 10 mM dNTPs mixture, 0.5 µl of each 10 mM primer 
and 0.1 µl Platinium Taq DNA polymerase (1 U) (Invitrogen, Carlsbarg, CA). The 
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volume was made up to 25 µl using double-distilled water. The PCR mixture was 
incubated in an automated thermocycler running a three step amplification protocol: 
an initial denaturing step at 94°C for 2 minutes followed by 30 cycles (of 94°C for 30 
seconds, 55-60°C for 30 seconds, 72°C for 0.5-1 minutes) and a final extension cycle 
of 72°C for 2 minutes. Following the first PCR amplification of cDNA derived from 
L4-6 rat DRG, a second identical amplification for increased sensitivity was carried 
out using 0.1 µl of the first PCR product as template. 
PCR products were resolved on a 1% agarose gel and bands were visualized 
using a PC-based image analysis system (ChemiDoc XRS System; Bio-Rad, 
Hercules, CA).  
5.1.10. Real-time PCR (qPCR) 
Following cDNA synthesis, real-time PCR (qPCR) was performed using the 
iQ5 SybrGreen Supermix (Bio-Rad Laboratories, Hercules, CA, USA) in an iQ5 
Real-Time PCR detection system (iQ™ optical system software). qPCR reactions 
were performed in 96-well plates (Microamp, Applied Biosystems) in triplicates. A 
final volume of 20 µl mastermix was prepared containing 10 µl of 2X SYBR green 
mastermix, 1 µl each of 5 µM forward and reverse primers and 1.5 µl of cDNA. The 
volume was made up to 20 µl using double-distilled water. Plates were centrifuged 
for 1 minute at 1000 xg and amplification was carried out using a two-step qPCR 
protocol with the initial denaturing step at 95°C for 3 minutes followed by 40 cycles 
(95°C for 10 seconds, 60°C for 30 seconds). Relative quantification values were 
identified by the 2-ΔΔCt method182 using levels of GAPDH mRNA as an internal 
control for normalization. 
5.1.11. Western blotting  
Cultured cells were collected 48 hours after transfection or infection and 
resuspended in lysis buffer consisting of 62.5 mM Tris–HCl, pH 6.8, 2% sodium 
dodecyl sulfate (SDS), 10% glycerol, 1X protease inhibitor cocktail (Roche, 
Mannheim, Germany), 1X phosphatase inhibitor (ThermoFisher Scientific, Carlsbad, 
CA). Samples were heated at 95°C for 5 minutes and sonicated for 4 seconds 
(Ultrasonicator Amplichron®, LKB instruments). The cell debris was removed by 
centrifugation (13,000 xg for 10 minutes) and supernatant was collected. Protein 
concentration was determined by using the Bio-Rad Dc protein assay (Bio-Rad, 
Hercules, CA) and 200 mM of dithiothreitol (DTT; Sigma-Aldrich, St. Louis, MO) 
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and 0.002% Bromophenol Blue (Sigma-Aldrich, St. Louis, MO) were added to each 
measured sample.  
Total cell extract was separated by SDS–polyacrylamide gel electrophoresis 
(Invitrogen, Carlsbarg, CA) (protein per lane: 80 µg of Neuro-2a cells, and 20 µg of 
DRG cells and HEK-293 cells), transferred overnight to an Immobilon-P membrane 
(0.45 µm; Millipore, Bedford, MA, USA) and blocked for 1 hour at room temperature 
with blocking buffer (5% non-fat milk in PBST). Blots were first incubated overnight 
at 4ºC with primary antibody diluted in incubation buffer (2% non-fat milk in PBST) 
followed by incubation with horseradish peroxidase (HRP)-conjugated secondary 
antibody diluted in incubation buffer (1:2000, Sigma-Aldrich, St. Louis, MO)for 1 
hour at room temperature. 
Membranes were stripped 30 minutes with western stripping buffer (Thermo 
Scientific, Carlsbarg, CA) and re-incubated overnight with alternative primary 
antibodies and their corresponding secondary antibodies coupled to HRP (1:2000, 
Sigma-Aldrich, St. Louis, MO). Finally membranes were treated with SuperSignal 
Western Dura Extended Duration Substrate (Thermo Scientific) according to 
manufacturer’s protocol and the relative intensity of each band was quantified using a 
PC-based image analysis system (ChemiDoc XRS System; Bio-Rad, Hercules, CA). 
5.1.12. Detection of β-galactosidase expression  
The culture medium was removed from the plates 48 hours after transfection 
and cells were washed twice with PBS and fixed with 4% paraformaldehyde (PFA; 
Sigma-Aldrich, St. Louis, MO) for 15 minutes at room temperature. The cells were 
washed three times with PBS and incubated at 37°C with X-gal stock solution (1 
mg/ml X-Gal [5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside dissolved in 
Dimethylformamide]) diluted 1:40 in warmed X-Gal dilution buffer (PBS 
supplemented with 2 mM MgCl2, 5 mM potassium ferrocyanide [K4Fe(CN)6].3H2O, 
5 mM potassium ferricyanide K3Fe(CN)6, 0.02% NP-40 and 0.01% sodium 
deoxycholate) until stained. The X-Gal stain was then removed and the cells were 
washed with PBS. 
5.1.13. Bacterial cell culture  
All bacterial cultures were grown in LB (lysogeny broth)183 or semi-solid agar 
plates containing LB and bacterial agar (1.5% w/v) (Nzytech, Lisbon, Portugal). LB 
was autoclaved at 121°C for 20 minutes at 15lb/inch2. Antibiotics were added as 
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required just before use. 
5.1.14. Chemically competent cells  
Competent cells used for transformation of plasmid DNA were prepared using 
CaCl2. A single bacterial colony was grown overnight in 3 ml of LB containing no 
antibiotics at 37°C. The saturated overnight culture was diluted 500-fold in 100 ml of 
LB containing no antibiotics. The cells were allowed to grow at 37°C until the optical 
density (OD) derived from absorbance measured at 600 nm reached between 0.3-0.4. 
Cells were pelleted by centrifugation at 10,000 xg for 10 minutes at 4°C. The 
supernatant was discarded and the pellet resuspended gently in 25 ml of ice-cold 100 
mM MgCl2. Cells were pelleted as before, resuspended in 4 ml of ice-cold 100 mM 
CaCl2 and kept on ice for 10 minutes. Glycerol was added to the bacterial suspension 
to a final concentration of 10% (v/v). Competent cells were aliquoted and stored at -
80°C. 
5.1.15. Bacterial transformation 
A volume of 50 µl of bacterial chemically competent cells was thawed on ice 
and cells were pipetted into 1.5 ml microcentrifuge tubes for each transformation. 1-5 
µl of ligation mix or 50 ng of plasmid DNA was added to the cells, mixed gently, and 
incubated on ice for 30 minutes. The cells were subjected to heat shock for 30 
seconds in a 42°C water bath and tubes were placed on ice for 10 minutes. 950 µl of 
pre-warmed SOC (super optimal broth184 with 20 mM added glucose) was added to 
each tube and incubated at 37°C for 1 hour with agitation. The transformed cells were 
plated in two different volumes on LB agar plates containing the appropriate 
antibiotic and incubated overnight at 37°C in a standard bacterial incubator. Two 
different volumes were plated to ensure well-spaced colonies in at least one sample. 
5.1.16. Plasmid amplification  
Positive clones were inoculated into and grown overnight with agitation at 
37°C and plasmid DNA was extracted using a Qiagen Plasmid Mini/ Maxi 
preparation kit (Valencia, CA) following the guidelines provided. 
 
5.1.17. DNA sequencing  
Plasmid (100 ng/µl) and BAC (200 ng/µl) DNA was sequenced by the Sanger 
dideoxy method in the Secugen S.L sequencing service (Madrid, Spain). Primers 
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were synthesized by Isogen Life Science (Veldzigt, the Netherlands) and were used at 
a final concentration of 5 µM. 
PCR products (3 ng/µl) amplified from cDNA derived from total RNA 
extracted from L4-6 rat DRG as described above, were sequenced by the Sanger 
dideoxy method at the University of Michigan DNA sequencing core (Ann Arbor, 
MI). Primers were synthesized by Invitrogen (Ann Arbor, MI) and were used at a 
concentration of 10 µM. All primers used for DNA sequencing are listed in Table 3 
and section 4.6.  
 
5.2. CELL CULTURE TECHNIQUES 
 
All cell culture manipulations were carried out under sterile conditions using 
standard aseptic techniques. 
5.2.1. Vero, Vero-derived, Neuro-2a, HEK-293 and SH-SY5Y cells 	  
5.2.1.1. Regeneration of cell lines 
Frozen cells were removed from the liquid nitrogen tank and quickly thawed 
by immersing the vial in a water bath at 37°C. Cells were rapidly transferred into a 15 
ml conical tube containing 3 ml of pre-warmed DMEM medium supplemented with 
10% FBS, 100U/ml penicillin and 100 µg/ml of streptomycin (F10 medium) to 
minimise the risk of cell damage by ice crystal formation and centrifuged. Cell pellets 
were resuspended in pre-warmed F10 medium and transferred to 100 mm cell culture 
dishes. 
 
5.2.1.2. Cryopreservation of cell lines 
Cells from one 100 mm cell culture dish were trypsinized until brought into 
suspension, centrifuged, resuspended in 1.8 ml freezing mixture (10% (v/v) dimethyl 
sulfoxide (DMSO) and 90% (v/v) FBS) and aliquoted in 2 cryovials, which were 
slowly cooled to -80°C by maintaining in a cryobox (Nalgene Mr Frosty, Sigma-
Aldrich, St. Louis, MO) containing 2-propanol and then stored in a liquid nitrogen 
tank. 
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5.2.1.3. Culture and passage procedure 
Cells were grown in 100 mm cell culture dishes or in 175 cm2 flasks in F10 
medium with the appropriate antibiotics if necessary (Table 2). They were incubated 
at 37°C in a humidified cell incubator with 5% CO2 and passaged when 75-80% 
confluent. The growth medium was removed by vacuum suction and cells were 
gently washed with PBS. Cells were incubated with 1 ml or 12.5 ml of the 
recombinant enzyme TrypLE (Substitute for Trypsin; Life Technologies, Paisley, 
UK) (for 100 mm cell dish or 175 cm2 flask respectively) until detached from the 
plate surface. An equal volume of F10 medium was added to the plate to neutralize 
the effect of the TrypLE and suspension was centrifuged in a 15 ml conical centrifuge 
tube at 200 xg for 5 minutes. The resultant cell pellet was resuspended in a small 
volume of fresh medium and seeded at a ratio of 1:10 in F10 medium with the 
appropriate antibiotics where necessary  (Table 2). 
 
5.2.1.4. Transfection  
Cells were transfected using the Lipofectamine-LTX and Plus reagent 
(ThermoFisher Scientific, Carlsbad, CA) according to the manufacturer’s 
instructions. One day prior to transfection, cells were seeded in a 35 mm cell culture 
dish to achieve 70-80% cell confluency on the day of transfection. In a sterile 1.5 ml 
microcentrifuge tube, 1 µg (plasmid) – 2 µg (BAC) DNA was diluted into 100 µl of 
Opti-MEM medium and mixed with Plus reagent in a ratio of 1:2 (plasmid DNA) or 
1:3 (BAC DNA). The mixture was incubated for 15 minutes at room temperature. In 
another microcentrifuge tube, 12 µl of Lipofectamine-LTX reagent was diluted in 100 
µl of Opti-MEM and added to the DNA-Plus mixture tube. The Lipofectamine, DNA 
and Plus mixture was allowed to form complexes over 30 minutes at room 
temperature. The cell culture medium was replaced with 0.8 ml Opti-MEM and the 
Lipofectamine-DNA-Plus mixture (200 µl) was gently added to the cells in drops. 
After 4 hours, the medium with transfection mixture was replaced with pre-warmed 
cell culture medium and cells were grown under normal conditions. 
5.2.2. Rat fetal dorsal root ganglion (DRG) neuronal cells 
 
5.2.2.1. Coating plates 
Prior to DRG cell culture, plates were coated adding 1 ml poly-D-lysine 
solution (PDL, 100 µg/ml) to each well of 12 well plate, then covered and incubated 
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with agitation overnight at 4°C. The next day the PDL solution was removed and 0.5 
ml laminin solution was added to each well  (10 µg/ml) (Sigma-Aldrich, St. Louis, 
MO). Plates were covered and incubated with agitation overnight at 4°C. Laminin 
was then removed, wells were rinsed with sterile water and plates were used or stored 
at 4°C. 
 
5.2.2.2. DRG cell extraction and culture procedure 
Dissection media containing dorsal root ganglia isolated from rat fetuses (as 
described in see section 5.5.1) were transferred into sterile 50 ml conic tube and 
centrifuge 1200 xg for 5 minutes at 4°C. Resulting pellets were dissociated in 6 ml of 
2.5 g/l Trypsin-1 mmol/l EDTA for 25 min at 37°C followed by centrifugation 1200 
xg for 10 minutes at 4°C. The pellets (containing DRG cells) were resuspended and 
washed with 10 ml of Neurobasal medium to break remaining tissue fragments. The 
cell suspension was filtered through a cell strainer (70 µm pore size; BD biosciences, 
San Jose, CA) to remove excessive debris followed by centrifugation at 2600 xg for 1 
minutes at 4°C. Cells were resuspended and plated in Neurobasal medium 
supplemented with 1X B27, 2mM Glutamax I, 0.5 µg/ml Albumax I, 50 U/ml 
penicillin G, 50 µg/ml streptomycin sulfate, and 0.1 µg/ml 7.0S nerve growth factor, 
at a density of 3X105 cells per well of PDL/laminin coated 12 well plate. 
One day after plating, expansion of non-neuronal dividing cells in the DRG 
culture was inhibited by addition of 5′-fluoro-2′-deoxy-uridine/uridine mixture 
(Sigma-Aldrich, St. Louis, MO) with a working concentration of 0.125 mg/ml for 
each. Half of the medium was changed three times per week. 
5.2.3. DRG infection 
DRG neurons were infected seven days after seeding at a multiplicity of 
infection (MOI) of 1 (plaque forming units per cell) during 90 minutes followed by 
change of half of the medium. 
 
5.3. BAC RECOMBINEERING TECHNIQUES 
5.3.1. Generation of mutants by homologous recombination  
The construction of mutants by lambda Red-mediated homologous 
recombination185,186 was carried out following the guidelines provided with a 
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commercial kit (Gene bridges, K001, version 2.7). Briefly, it involved the following 
steps: 
 
5.3.1.1. Generation of the linear targeting fragment flanked by homology arms  
A targeting fragment including an antibiotic selection marker gene flanked by 
homologous sequence arms of DNA shared by the two molecules that recombine, 
was generated by PCR using customized oligonucleotides. The 5’ oligonucleotide 
consisted of a 50 nucleotides homology arm (which allows recombination with the 
homologous sequence 5’ of the intended insertion site), followed by a 20-nucleotide 
stretch, which primes the 5’ end of the PCR amplification of the targeting fragment. 
The 3’ oligonucleotide was similarly designed, with a stretch of 50 nucleotides that is 
homologous to the region 3’ of the intended insertion site, followed by a 20-
nucleotide stretch that primes the 3’ end of the PCR amplification of the targeting 
fragment. Linear targeting fragments of the constructed mutants were generated as 
follows: 
5.3.1.1.1. 27_22_Or  
For construction of the 27_22_Or vector, the targeting fragment was 
generated by PCR amplification of the Sh ble gene (conferring zeocin resistance, 
ZeoR) using oligonucleotides I27DZ and US3Z (see Table 2) and plasmid pDRIVE-
CAG as template DNA. The resulting targeting fragment was recombined into the 
∆IR vector backbone (Khalique et al, submitted to J Gene Med). 
5.3.1.1.2. 22_4 and 22_4_Or  
For construction of the 22_4 and 22_4_Or vectors, the targeting fragment was 
generated by PCR amplification of the RP-KanR cassette composed by the 
Escherichia coli (E. coli) ribosomal S12 (rpsL) gene (RP) which results in 
streptomycin sensitivity and the aminoglycoside phosphotransferase (aph) gene 
which confers kanamycin resistance (KanR) using oligonucleotides I4OS5 and I43P 
for 22_4 construction and oligonucleotides I45P and I43P for 22_4_Or construction 
(see Table 2). Plasmid pSK+KanaRpsL was used as template DNA. Both targeting 
fragments were recombined into the ∆IR backbone. 
5.3.1.1.3. 27_22_4_Or  
For 27_22_4_Or construction, the targeting fragment was generated by PCR 
amplification of the Sh ble gene using oligonucleotides I27DZ and US3Z (see Table 
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2) and plasmid pDRIVE-CAG as template DNA. The resulting targeting fragment 
was recombined into the 22_4_Or backbone. 
5.3.1.1.4. 27_4_Or2 
The targeting fragment used for construction of mutant 27_4_Or2 was 
generated by digestion of plasmid pSKOrisZ with XhoI and SpeI restriction enzymes 
and the resulting fragment was recombined into the 22_4_Or backbone. 
For the construction of pSKOrisZ, the Sh ble gene was amplified by PCR 
using primers I27DZ and PACSPE (see Table 2) and plasmid pDRIVE-CAG as 
template DNA. The resulting fragment was ligated into the pGEM-T Easy vector 
generating the pGEM-T EasyZ vector. This was then digested with NotI/SpeI to 
obtain the ZeoR cassette which was then religated into the pSKC481.9 plasmid to 
generate pSKOrisZ. 
5.3.1.1.5. 27_4_Or2_β22  
For 27_4_Or2_β22 construction, the targeting fragment was generated by 
PCR amplification of the beta lactamase (bla) gene (conferring ampicillin resistance, 
AmpR) using oligonucleotides I27DA and IRTGA (see Table 2) and plasmid 
pSK+KanaRpsL as template DNA. The resulting targeting fragment was recombined 
into the 27_4_Or2 backbone. 
5.3.1.1.6. 27_4_Or2_β22_β47  
For 27_4_Or2_β22_β47 construction, the targeting fragment was generated by 
PCR amplification of the Sh ble gene using oligonucleotides IRTGZ and Z143P (see 
Table 2) and plasmid pDRIVE-CAG as template DNA. The resulting targeting 
fragment was recombined into the 27_4_Or2_β22 backbone. 
The position and length of the deletions of each of these HSV-1 vectors are 
listed in Table 1. 
5.3.1.1.7. FXN-p 
For FXN-p construction, the targeting fragment was generated by PCR 
amplification of the RP-KanR cassette using oligonucleotides T7TN5 and FL511K 
(see Table 2) and plasmid pSK+KanaRpsL as template DNA. The resulting targeting 
fragment was recombined into the FXN-WT backbone (see Supplementary figure 
2). 
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5.3.1.1.8. FXNinlZ 
For FXNinlZ construction, we first deleted all of the genomic insert sequences 
3’ to FXN exon 2 up to the sacB gene located within the BAC vector, replacing this 
region by a ZeoR cassette. In a second round of recombination we next replaced the 
ZeoR cassette with the F2ALRK cassette which encodes the FXN cDNA from exon 2 
to 5a, the Porcine teschovirus-1 (PTV1) 2A sequence187 including a 5’ linker 
sequence encoding glycine-serine-glycine, the E. coli lacZ gene, the polyadenylation 
(polyA) signal derived from the simian virus 40 (SV40), a loxP site and a RP-KanR 
cassette (see Supplementary figure 2). 
For construction of the F2ALRK targeting plasmid, a FXN cDNA fragment 
comprising exons 2, 3, 4 and 5a, was amplified and fused at the 3’ end to the PTV1 
2A sequence by PCR using the plasmid pLVfrat 126  as template DNA and the primers 
R2 and R3 (Table 2). This PCR product was digested by PstI/NcoI restriction 
enzymes and cloned into Bluescript KSII+ digested with PstI/NcoI to generate the 
pF2A plasmid. An NcoI/PacI fragment containing the lacZ gene and the SV40 polyA 
signal from the pDRIVE-CAG plasmid was then ligated into the pF2A plasmid 
digested with NcoI/PacI to generate the pF2AL plasmid. The KanR gene was next 
amplified by PCR from the template plasmid pSK+KanaRpsL using the primers R5 
and R6 (Table 2). The PCR product was digested with PacI/SalI and ligated into 
pF2AL digested with PacI/SalI to generate the pF2ALRK targeting plasmid. The 
final F2ALRK cassette was then generated by digestion of the pF2ALRK plasmid 
with PstI/SalI restriction enzyme. 
 
Table 1. Deletions in wild type HSV-1 F strain 
Mutant Nucleotide positions  Total kb 
27_22_Or  113217-132468 19.2 
22_4  146029-151773 5.7 
22_4_Or  146874-151773 4.8 
27_22_4_Or 113217-132468 
146874-151773 
24 
27_4_Or2 113217-131408 
146874-151773 
23 
27_4_Or2_β22  113217-131672 23.3 
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146874-151773 
27_4_Or2_β22_β47  113217-131672 
146312 -151773 
23.8 
 
5.3.1.2. Transformation with Red/ET expression plasmid  
A sample of glycerol stock of E. coli strain DH10B168,169 containing the target 
BAC was streaked on a LB agar plate containing the appropriate antibiotics. The 
plate was incubated overnight at 37°C in a bacterial incubator. Next day one colony 
from the streaked plate was inoculated in a 1.5 ml microcentrifuge tube containing 1 
ml of LB containing the appropriate antibiotics and incubated on shaker at 37°C 
overnight.  
The second day, two microcentrifuge tubes containing 1.4 ml of LB 
conditioned with the appropriate antibiotics were inoculated with 30 µl of the 
overnight culture and incubated at 37°C for 2 hours with agitation. After incubation, 
electrocompetent bacterial cells were prepared by three consecutive washes with ice-
cold water, centrifugation at 11,000 xg for 1 minute at 2°C between each, followed 
by a final resuspension in 50 µl ice-cold double-distilled water.  
For transformation, 1 µl of the pRed/ET plasmid (100 ng) was added to the 
electrocompetent cells of one of the microcentrifuge tubes and mixed gently. The 
other tube was used as an electroporation control (without pRed/ET). Electroporation 
was performed in ice-cold cuvettes (Bio-Rad Laboratories, Inc., 1 mm electrode gap) 
using a Bio-Rad MicroPulser at 1.8 kV, untruncated time setting. After 
electroporation, 1 ml of pre-warmed SOC medium was added to the cuvettes to 
facilitate recovery of the cells which were then incubated at 30°C for 1 hour with 
shaking. Cells were spread onto LB agar plates containing the appropriated 
antibiotics (see Table 2) and tetracycline (3 µg/ml) and incubated overnight in a 
bacterial incubator at 30°C. 
 
5.3.1.3. Insertion in the genome of linear fragments with desired mutations 
using selection markers and reporter genes 
A single colony was picked from the LB plate containing Red/ET plasmid and 
target BAC and inoculated into a 1.5 ml microcentrifuge tube containing 1 ml LB 
broth with the appropriate antibiotics (see Table 2) and tetracycline (3 µg/ml). The 
tubes were incubated overnight at 30°C with agitation. 
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On the next day four microcentrifuge tubes (2 for experiment and 2 for 
control) containing 1.4 ml fresh LB supplemented with the appropriate antibiotics 
(see Table 2) and 3 µg/ml tetracycline were inoculated with 30 µl of the saturated 
overnight culture. All the four tubes were incubated at 30°C until the OD derived 
from absorbance measured at 600 nm reached between 0.3-0.4. Expression from the 
pRed/ET plasmid was induced in two tubes (1 from the experiment and 1 from the 
control) by addition of 50 µl of 10% L-arabinose and incubation for 45 minutes at 
37°C before chilling on ice for 15 minutes. The electrocompetent cells were prepared 
as described above (see section 5.3.1.2). For transformation, 100 ng (1-2 µl) of the 
linear targeting fragment was added to the electrocompetent cells on ice (both L-
arabinose-induced and uninduced experimental tubes). Electroporation was 
performed on all the four cultures (induced and uninduced experimental tubes, 
induced and un-induced control tubes) in ice-cold cuvettes (1 mm electrode gap) 
using a Bio-Rad MicroPulser at 1.8 kV, untruncated time setting. After 
electroporation, 1 ml of pre-warmed SOC medium was added to the cuvettes to 
facilitate recovery of the cells which were then incubated at 37°C for 1 hour with 
shaking and inoculated onto LB agar plates containing the appropriate antibiotics (see 
Table 2). The next day, several independent colonies were picked and tested for 
correct recombination by colony PCR or restriction digest analysis of purified BAC 
DNA. 
5.3.2. Generation of mutants by Cre recombinase-mediated site-specific DNA 
insertion or deletion  
Construction of mutants by Cre recombinase-mediated site-specific DNA 
insertion into the loxP site of the BAC plasmid or deletion of selection marker 
cassettes was carried out following the protocol previously described by Saeki and 
co-workers.177   
 
5.3.2.1. Plasmid insertion  
This strategy was used for construction of vectors 27_22_4_Or2, 27_4_Or3, 
27_22_4_OrG, 27_4_Or2G, 27_4_Or2_β22 GFP (see Supplementary figure 1) and 
insertion of the green fluorescent protein (GFP) reporter cassette into each of the 
three FXN BAC DNAs.  
Electrocompetent bacterial cells containing the BAC DNA (27_22_4_Or, 
27_4_Or2, FXN-WT, FXN-p or FXNinlZ) were prepared as described above in 
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section 5.3.1.2. The cells were electroporated with a mixture containing 10 ng each 
of the temperature sensitive (ts) helper plasmid pCTP-T (which expresses Cre 
recombinase in trans) and the insertional shuttle plasmid.  
Insertional shuttle plasmids used were: 1) the plasmid pHG (which contains a 
loxP site, the IE4/5 promoter, the GFP reporter gene (gfp), the HSV-1 packaging 
signal and the AmpR gene) for the generation of 27_22_4_Or2, 27_4_Or3 and 
labelling of the three FXN BAC DNAs; 2) the plasmid pLCG (which contains a loxP 
site, the citomegalovirus (CMV) promoter, the GFP reporter gene and AmpR gene) 
for the generation of 27_22_4_OrG and 27_4_Or2G; or 3) the plasmid pLCG-ZEO 
(which contains a loxP site, the CMV promoter, the GFP reporter gene and the ZeoR 
gene) for the generation of 27_4_Or2_β22 GFP.  
After electroporation, cells were resuspended into 1 ml SOC medium 
containing heat-inactivated tetracycline (20 µg/ml) to induce Cre expression in two 
tubes and incubated for 4 hours at 30°C (permissive temperature for the helper 
plasmid pCTP-T) with shaking. The integrated recombinants were selected at 43°C 
(restrictive temperature for the pCTP-T) on LB agar plates supplemented with the 
appropriated antibiotics (see Table 2). The next day, several independent colonies 
were picked and tested for correct recombination by colony PCR or restriction digest 
analysis of purified BAC DNA. 
 
5.3.2.2. BAC insertion 
This strategy was used for construction of the 27_4_Or2_β22 FXNInLZ 
vector. Electrocompetent bacterial cells containing the 27_4_Or2_β22 BAC DNA 
were prepared as described above in section 5.3.1.2. The cells were first 
electroporated with 10 ng of helper plasmid pCTP-T. The resulting culture was plated 
onto LB plates containing the appropriate antibiotics (see Table 2) and plates were 
incubated overnight at 30°C. On the next day, a single colony was picked and 
inoculated in 1ml LB broth with the appropriated antibiotics overnight at 30°C with 
agitation. On the third day, electrocompetent bacteria containing the 27_4_Or2_β22 
BAC and the pCTP-T plasmid were electroporated with 100ng of the FXNinlZ BAC 
(FXNinlZ BAC without the GFP cassette). Cells were then transferred into 1 ml SOC 
medium containing heat-inactivated cTc (20 mg/ml) to induce Cre expression and 
incubated for 4 hours at 30°C with shaking. The resulting culture was then plated 
onto LB plates containing appropriate antibiotics (see Table 2), 100mM isopropyl β-
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D-1-thiogalactopyranoside (IPTG) and Xgal reagents, which induce expression of the 
lac operon in E. coli to detect β-galactosidase activity thus allowing blue/white 
screening of the colonies. Plates were incubated overnight at 43°C. The next day, 
several independent colonies were picked and tested for correct recombination by 
colony PCR or restriction digest analysis of purified BAC DNA. 
 
5.3.2.3. Selection marker cassette deletion 
Deletion of the RP-KanR cassette from the FXN-p and FXNinlZ mutants was 
performed as follows. Electrocompetent bacterial cells containing FXN-p or FXNinlZ 
BAC DNA were prepared as described above in the section 5.3.1.2. The cells were 
electroporated with 10 ng of the plasmid pCTP-T. After electroporation, cells were 
resuspended into 1 ml SOC medium containing heat-inactivated tetracycline (20 
µg/ml) to induce Cre expression and incubated for 4 hours at 30°C with shaking. The 
integrated recombinants were grown at 43°C (restrictive temperature for the pCTP-T) 
on LB agar plates supplemented with the appropriated antibiotics (see Table 2). Next 
day, screening of positive recombinants was achieved by negative selection on LB 
agar plates supplemented with the appropriated antibiotics in presence and absence of 
Kanamycin. The next day, several independent colonies were picked and tested for 
correct recombination by colony PCR or restriction digest analysis of purified BAC 
DNA. 
 
Table 2. Selection markers expressed by HSV-1 and FXN mutants. 
Mutant Selection markers* 
∆IR Chloramphenicol, Ampicillin  
27_22_Or  Chloramphenicol, Ampicillin, Zeocin 
22_4  Chloramphenicol, Ampicillin, Kanamycin  
22_4_Or  Chloramphenicol, Ampicillin, Kanamycin  
27_22_4_Or Chloramphenicol, Kanamycin, Zeocin  
27_22_4_Or GFP Chloramphenicol, Ampicillin, Kanamycin, 
Zeocin 
27_22_4_Or2 
 
Chloramphenicol, Ampicillin, Kanamycin, 
Zeocin 
27_4_Or2 Chloramphenicol, Kanamycin, Zeocin  
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27_4_Or2 GFP 
 
Chloramphenicol, Kanamycin, Zeocin  
Ampicillin 
27_4_Or3 
 
Chloramphenicol, Ampicillin, Kanamycin, 
Zeocin 
27_4_Or2_β22  Chloramphenicol, Ampicillin, Kanamycin 
27_4_Or2_β22_β47  Chloramphenicol, Ampicillin, Zeocin  
 
27_4_Or2_β22 GFP Chloramphenicol, Ampicillin, Kanamycin, 
Zeocin 
27_4_Or2_β22 
FXNinlZ 
Chloramphenicol, Ampicillin, Kanamycin 
FXN-p Chloramphenicol, Ampicillin 
FXNinlZ Chloramphenicol  
*Antibiotic final concentration: chloramphenicol 15 µg/ml, ampicillin 50µg/ml, 
zeocin 25 µg/ml, kanamycin 15 µg/ml.  
5.3.3. Verification of modified BAC by DNA sequencing  
Positive recombinant BAC clones were purified by a second round of 
electroporation (as described above, section 5.3.1.2) and DNA samples were sent to 
the sequencing service for final confirmation (see section 5.1.17) using 
oligonucleotides designed for sequencing across the recombination junctions. The 
oligonucleotides used for sequencing of mutants and their sequences are listed in 
Table 3 and section 4.6. 
 
Table 3. Oligonucleotides used for sequencing of HSV-1 and FXN mutants. 
Mutant Oligonucleotides  
27_22_Or  GK3P, ICP225’OUT  
22_4  RPREV, SEQK5  
22_4_Or  RPREV, SEQK5  
27_22_4_Or  GK3P, ICP225’OUT  
27_22_4_Or GFP S1LOXHSV, SU2LOXHSVUL4 
27_22_4_Or2 S1LOXHSV, SU2LOXHSVUL4 
27_4_Or2 GK3P, ICP225’OUT  
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27_4_Or2 GFP S1LOXHSV, SU2LOXHSVUL4 
27_4_Or3 S1LOXHSV, SU2LOXHSVUL4 
27_4_Or2_β22  GK3P, AMP3’OUT  
27_4_Or2_β22_β47  MARIZEO, Z5PRV  
27_4_Or2_β22 GFP S1LOXHSV, SU2LOXHSVUL4 
27_4_Or2_β22  
FXNinlZ 
S1LOXHSV, SU2LOXHSVUL4 
RPrev (RP-KanR   deletion) 
FXN-p 
 
SEQK5, 3’TN5pr (RP-KanR  insertion) 
RPrev (RP-KanR   deletion) 
FXNinlZ prG, LACZ3OUT  
5.4. VIRAL AMPLIFICATION TECHNIQUES 
5.4.1. Viral stock preparation  	  
Table 4. Cell lines used for propagation and titering of viral stocks. 
HSV-1 BAC Cell line 
WT, IR Vero 
27_22_Or  2-2 
22_4, 22_4_Or E5 
27_22_4_Or (GFP)  
27_22_4_Or2,  
27_4_Or2 (GFP)  
27_4_Or3  
27_4_Or2_β22 (GFP/FXNInLZ) 
27_4_Or2_β22_β47 
 
 
7b 
  
5.4.1.1. Seed stock 
According to the mutations present in the viral mutant, appropriate permissive 
cells (see Table 4) were seeded in a 35 mm cell culture dish to obtain 70% 
confluence on the day of transfection. Cells were transfected with 2 µg of BAC DNA 
encoding viral genome as described above in section 5.2.1.4 and 4 hours after 
transfection the cells were overlaid with 0.7% sterile agarose dissolved in F2 medium 
(DMEM supplemented with 2% FBS, 100U/ml penicillin G and 100 µg/ml of 
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streptomycin sulfate) and incubated at 37°C. Viral viability and propagation were 
evident by visible cytopathic effects (CPE) in cells and the formation of plaques. The 
times for these visible changes to appear varied dramatically depending on the vector 
backbone and the cell line. If the virus was able to replicate, a single plaque was 
picked using a P 20 Gilson pipette stabbing through the agarose into the cells. The 
agarose plug with the cells were transferred into a 0.5 ml microcentrifuge tube 
containing 40 µl of FBS and stored at -80°C until further use. Such a single plaque 
sample was used to infect fresh Vero cells seeded in a 35 mm culture dish for WT 
and ∆IR viral stocks or the appropriate complementing Vero-derived cells seeded in a 
3.8 cm2 well from a 12 well plate for the rest of the viral stocks. When the majority of 
the cells had rounded up but were not detached from the well surface, they were 
harvested by lifting the cells with a plastic scraper into the medium which was then 
subjected to three freeze-thaw cycles followed by sonication to release intracellular 
viral particles. Cell debris was removed by centrifugation (2060 xg for 10 minutes) 
and the clarified supernatant was collected and stored at -80°C. 
 
5.4.1.2. Working stock  
To prepare a regular WT or IR master stock, Vero cells were seeded in a 
100mm cell culture dish and infected with 50 µl of the seed stock in 8 ml of F2 
medium. After 1-2 days when CPE were obvious, cells were harvested and the 
supernatant containing the virus collected and stored as described for seed stock 
preparation. 
To prepare a regular master stock from the seed stock of the rest of the 
mutants, two rounds of amplification were performed. For the first one (termed 
second amplification), appropriated complementing cells for each mutant (see Table 
4) were seeded in a 35 mm cell culture dish and infected with 1/70 (for 27_22_Or and 
22_4_Or) or 1/30 of the seed stock (for 27_22_4_Or2, 27_4_Or2, 27_4_Or3, 
27_4_Or2_β22 and 27_4_Or2_β22_β47) in 1 ml of F2 medium. When CPE were 
obvious (depending on the virus to be grown), cells were harvested and the 
supernatant containing the virus collected and stored as described for seed stock 
preparation. To perform the second round of amplification (termed third 
amplification), the same process was repeated in a 100 mm cell culture dish. Viral 
preparations were collected and stored in aliquots at -80°C. 
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5.4.1.3. Large-scale stock: 27_4_Or2_β22 GFP and 27_4_Or2_β22FXNlnZ 
mutants 
For large-scale propagation, eight 850 cm2-roller bottles were seeded with 
1x107 7b cells in F10 media supplemented with 0.025M HEPES per bottle to buffer 
the medium if the roller bottles were not incubated in a CO2 incubator. When the 
monolayer reached approximately 75% of confluence (2-3 days post seeding), cells 
from each roller bottle were infected with 1/8 of the total volume of the second 
amplification regular stock in fresh 30 ml of F2 medium and incubated at 37°C for 90 
minutes. At the end of this adsorption period, 50 ml of F2 media supplemented with 
0.025M HEPES was added to each bottle which was incubated at 37°C until CPE 
became visible (3-4 days). Cells were then detached into the media by swirling the 
media around the inside of the roller bottle and the cell suspension was centrifuged at 
2060 xg for 10 min at 4°C. The supernatant was decanted into a 500 ml 
polypropylene centrifuge bottle and stored on ice. The pellet was resuspended in cold 
PBS and centrifuged again at 2060 xg for 10 min at 4°C. The resulting supernatant 
was added to the previous stored supernatant and the pellet was stored in PBS at 4°C. 
To harvest the viruses from the supernatant, combined supernatants were 
centrifuged for 1 hour at 18,600 xg in a Beckmann preparative centrifuge JLA10.5 
rotor. Meanwhile the stored pellet suspension was subjected to manual 
homogenization and used to resuspend the resulting second pellet. The final 
suspension was stored 90 minutes at 4°C and transferred to two Beckman ultra-clear 
centrifuge tubes. A volume of 3ml of 50% Iodixanol (OptiPrep, Axis-shield density 
gradient media, Alere Technologies AS, Oslo, Norway) was added to each tube and 
the tubes were topped with PBS, followed by centrifugation for 35 minutes at 
131,500 xg in a SW32 rotor in a Beckmann XL-90 ultracentrifuge. Finally, the 
bottom 7.5 ml (3 ml 50% opti-prep, 4.5 ml PBS and virus) were collected, gently 
mixed and stored at -80°C. 
 
5.4.1.4. Viral stock Purification: iodixanol gradient 
For large-scale viral stock purification, the concentrated solution was 
transferred to a 13 ml Beckman pollyallomer quick-seal tube adding 15 ml 20% 
Iodixanol (OptiPrep, Axis-shield density gradient media, Alere Technologies AS, 
Oslo, Norway) followed by centrifugation for 4.5 hours at 342,000 xg in a NVT65 
rotor in a Beckmann XL-90 ultracentrifuge. Viral particles were banded by the self-
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generated gradient towards the bottom of gradient while any contaminating cellular 
material was banded at lower densities. To harvest the virus, a needle was inserted to 
vent the top of the tube, and using another needle with a 5 ml syringe, 5 ml of the 
viral band from the bottom of the gradient was aspirated. This extracted viral solution 
was centrifuged (19500 xg for 35 minutes at 4ºC), resuspended in 0.5 ml of cold PBS 
and stored in aliquots at -80°C. 
 
5.4.1.5. Viral stock titration  
5.4.1.5.1. Assay for infectious particles 
Titration assays to detect infectious virions were performed by infecting 
monolayers of the appropriate complementing cells (see Table 4) with serial dilutions 
of the viral preparation in F2 medium. After absorption for 90 minutes, the medium 
was replaced with 0.7% sterile agarose dissolved in F2 medium to prevent secondary 
spread of virus. Following overnight incubation, cells were fixed with 4% 
paraformaldehyde (PFA; Sigma-Aldrich, St. Louis, MO) and the agarose was 
removed. Cells were incubated in blocking buffer (PBS containing 1% FBS and 0.2% 
Triton X-100) for 30 minutes at room temperature and incubated with a polyclonal 
anti-HSV-1 antibody (1:1000) for 2 hours at room temperature. After incubation, 
cells were washed 3 times in PBS and then incubated with anti-rabbit secondary 
antibody/peroxidase conjugate (1:2000, Sigma-Aldrich, St. Louis, MO) for 1 hour at 
room temperature. Peroxidase-labelled cells were visualized by incubation with a 
mixture of 0.05% 3, 3’-Diaminobenzidine (DAB; Acros Organics, Geel, Belgium) 
and 0.015% hydrogen peroxide (H2O2; Panreac, Barcelona, Spain) for 5 minutes. The 
DAB mixture was removed and cells were washed once with PBS to stop the staining 
process. HSV-1 positive cells (stained brown) were counted by microscopy to 
calculate infectious HSV-1 particles per millilitre (IP/ml). 
5.4.1.5.2. Assay for plaque forming units  
Titration assays for plaque-forming units were performed by infecting in 
suspension 7X105 appropriated complementing cells (see Table 4) with serial 
dilutions of the viral preparation in F2 medium. Infected cells were rotated in a 
rotisserie manner on a LabQuake rotary shaker at 37°C for 90 minutes and then 
plated in 6 well plates. Next day, the medium was removed and replaced with DMEM 
containing 1.25% methylcellulose to prevent secondary spread of virus. Plaque 
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formation (usually 4-5 days after infection) was verified by confocal microscopy and 
quantified by counting plaque forming units (PFU) by removing medium and staining 
with crystal violet (2 mg/ml) in a 50:50 mixture of methanol and deionized water. 
One hour after staining, the wells were washed with water and plaques counted by 
microscopy. 
 
5.4.1.6. Cell complementation analysis 
Viral replication in non-complementing and complementing cell lines was 
determined following infection of the assayed cells at MOI 1 (infectious particle per 
cell) in F2 medium. Cells were incubated at 37°C for 90 minutes to allow the virus to 
be absorbed after which media was replaced with fresh F2 medium and the cultures 
incubated at 37°C for 6 days. Cells were harvested into the medium which was 
subjected to three freeze-thaw cycles followed by sonication. The cell lysate was 
centrifuged at 2060 xg for 10 minutes and titration by infected cells assay of the viral 
supernatant was performed as described above. 
5.4.2. In vitro multi-cycle growth kinetics assay 
Approximately 1.8X105 appropriate permissive cells (see Table 4) were 
seeded in 35 mm cell culture dishes and infected at MOI of 0.05 (infectious particle 
per cell) in F2 medium. Cells were incubated at 37°C for 90 minutes to allow the 
virus to be absorbed after which the medium was replaced with fresh F2 medium and 
the cultures incubated at 37°C for stated time points. Progeny viruses were harvested 
into the medium which was then subjected to three freeze-thaw cycles followed by 
sonication. The cell lysate was centrifuged at 2060 xg for 10 minutes and titration for 
infectious particles in the viral supernatant was performed as described above. 
 
5.5. ANIMAL TECHNIQUES 
5.5.1. Isolation of rat fetal dorsal root ganglia 
Sprague Dawley female rats (day 17 p.c. (post coitum)) (Charles River, 
Portage, MI) were sacrificed in a CO2 chamber. The uterine horns were dissected out 
carefully, and place in ice-cold dissection Leibovitzs L-15 medium supplemented 
with 25 U/ml penicillin G and 25 µg/ml of streptomycin sulfate. Each embryo was 
separated from its placenta and surrounding membranes. The brain region, dark red 
organs and as much blood as possible were removed from the embryos in order to 
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isolate the spinal cords under the microscope and place them in a clean culture dish 
with dissecting medium. Dorsal root ganglia were separated from both sides of the 
spinal cord which was then discarded. 
5.5.2. Viral inoculation of rat footpads   
Under isoflurane anesthesia, male Sprague-Dawley rats (Charles River, 
Portage, MI) weighing 200 to 250g were inoculated in the plantar surface of both 
hind feet with 30µl of PBS containing 1.5 x 106 pfu of the 27_4_Or2_β22 FXNinlZ 
vector or 3 x 106 pfu of the control 27_4_Or2_β22 GFP vector. Three rats were 
inoculated with each vector.  
5.5.3. Isolation of dorsal root ganglia from adult rats 
Seven days or one month after inoculation, animals from each group were 
treated by intraperitoneal injection with 300 mg/kg Ketamine and 30 mg/kg Xylazine 
and sacrificed. L4-6 rat DRG were extracted and stored at -80ºC.  
 
5.6. STATISTICAL ANALYSIS 	  
Spreadsheet and graphical representations were performed using Microsoft 
Excel 2007 software. 
Data are expressed as the mean ± standard deviation (SD) of three 
experiments. Statistical comparison of the data sets was performed by paired two-
tailed Student’s t test. The differences are given with their corresponding P value, 
which is the probability that the difference occurred merely by chance under the null 
hypothesis. P values below 0.05 are considered statistically significant. 
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6. RESULTS 
6.1. HSV-1 deletion mutants defective for IE gene expression 
For the generation of a recombinant vector for neurological gene therapy of 
Friedreich’s ataxia (FRDA), our first goal was the construction of a nonreplicative 
herpes simplex virus type-1 (HSV-1)-derived genomic vector with a high cargo 
capacity while retaining its growth capacity for large scale production. To increase 
the transgene capacity of the HSV-1 viral genome as a vector and to facilitate further 
modifications, we previously deleted the entire internal repeat (IR; joint) region to 
remove all duplicated sequences in the genome, thus ensuring unambiguous targeting 
of the remaining gene copies in the terminal repeat (TR) region (Khalique et al, 
submitted to J Gene Med). In concordance with studies of similar mutants 
constructed previously188,189,190, we observed that this ∆IR mutant undergoes efficient 
lytic replication in Vero cells, indicating that only a single copy of all the genetic 
elements in HSV-1 is sufficient for efficient viral growth in culture (Khalique et al, 
submitted to J Gene Med).  
Since other non-replicative genomic HSV-1 vectors based on the elimination 
of IE gene expression have already been used in human clinical trials 53, we next 
modified our ∆IR mutant by further deletion of the two essential IE genes encoding 
ICP27 and ICP4. Furthermore, of special relevance to this aim, it should be noted that 
the deletion of the entire IR region eliminates one copy of the IE gene ICP0, one 
copy of the IE gene ICP4 and truncates the IE4/5 promoter of the IE gene ICP22. 
Although the US1 protein coding region for ICP22 is in the US component of the 
HSV-1 genome, the promoter and the 5’ portion of the transcribed region reside in 
the flanking IR sequence. 
The UL54 gene, which encodes ICP27, is separated from the IR region by the 
UL55 and UL56 genes, which have been described to be nonessential in the context of 
wild type (WT) HSV-1.191 Therefore, to eliminate ICP27 expression and 
simultaneously increase transgene capacity we extended the ∆IR deletion by 
eliminating UL56, UL55 and UL54, to generate the mutant 27_22_Or (Figure 6a, our 
nomenclature includes “Or” to indicate the copy number of origins of replication, the 
relevance of which will become clear below). As expected, this 27_22_Or mutant 
was able to replicate in the ICP27-complementing 2-2 cell line 172, indicating that the 
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UL55 and UL56 genes are also nonessential for lytic replication in the background of a 
HSV-1 genome deleted for IR and ICP27. Inability of this mutant to grow in Vero 
cells confirmed that the essential ICP27 gene had indeed been deleted (Figure 7a). 
In parallel to the deletion described above, to eliminate ICP4 expression, we 
generated the 22_4 mutant from the ∆IR backbone by deleting the remaining copy of 
the ICP4 gene as well as the adjacent sequences in the TR region, which include the 
IE4/5 promoter region. The IE4/5 promoter is quite unusual in that it contains a viral 
origin of replication, oriS, embedded within the transcriptional regulatory sequences 
between the TATA box and the TAATGARAT motifs that confer IE kinetics to 
ICP22 and ICP47 (Figure 6b). This viral replication origin was previously 
demonstrated to be nonessential since a fully replicative HSV-1 mutant lacking both 
copies of the oriS region was isolated. 192 Surprisingly, however, our 22_4 mutant was 
unable to grow on the ICP4-complementing E5 cell line 54, which supports replication 
of other ICP4-defective mutants.  
We hypothesized that the deletion of the remaining copy of oriS in the 
multiply deleted ∆IR backbone could be responsible for the loss of replication 
competence. We thus generated the 22_4 _Or mutant by deleting only the ICP4 gene 
and leaving intact the adjacent oriS; this mutant was able to replicate in E5 cells, 
confirming that the absence of oriS copies results in a major growth impairment in the 
22_4 mutant. Inability of this mutant to grow in Vero cells confirmed that both copies 
of the essential ICP4 gene had indeed been deleted (Figure 7a). 
6.2. Growth deficiency of HSV-1 IE mutants can be compensated for by addition 
of the oriS region 
Since we had successfully generated viable mutants deleted for either ICP27 
or ICP4 in the background of our ∆IR backbone, our next step was to combine the 
two deletions in ∆IR to eliminate both ICP27 and ICP4 expression to generate the 
27_22_4_Or mutant genome (Figure 6a). Unexpectedly, we were unable to obtain 
viral plaques when this mutant was transfected into the ICP4/ICP27-complementing 
cell line 7b. 51 Since as described above, we had just observed that the growth defect 
of the 22_4 mutant could be rescued by addition of an oriS copy, we tested whether 
the same strategy could be used to achieve replication competence of the 27_22_4_Or 
mutant, since the ΔIR deletion in this mutant removed the oriS copy embedded in the 
ICP22 IE 4/5 promoter region. We thus generated the 27_22_4_Or2 mutant (Figure 
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6a) in which an oriS copy embedded in the IE4/5 promoter region linked to the GFP 
reporter gene, was inserted ectopically into the 27_22_4_Or genome at the UL3-UL4 
intergenic region (Supplementary figure 1), which has previously been described as 
a non-disruptive insertion site for transgene cassettes. 
 
 
 
 
Figure 6. Structure of non-replicative genomic HSV-1 mutants. 
a. Schematic representation of HSV-1 WT and HSV-1 mutant linear genomes. The unique 
long (UL) and the unique short (US) segments (open boxes) are shown flanked by the internal 
repeat (IR) and the terminal repeat (TR). The unique origin of replication oriL is present in 
the UL segment (open circle), the two origins of replication oriS are present in IR and TR 
(filled circle), and the oriS (filled circle) inserted ectopically between the UL3 and UL4 genes 
by Cre/loxP recombination Inverted peaks represent HSV-1 sequence deletions. Deletions 
regarding immediate early genes (Δ, IE mutations) and number of oriS copies are listed next 
to each mutant; “p” represents promoter sequence and “β” TAATGARAT sequence. 
b. Schematic representation of the 822-bp intergenic HSV-1 region between the divergently 
transcribed genes encoding ICP4 and ICP22 or ICP47 (ICP22/47). The positions of the 
TAATGARAT elements (open arrowheads), binding sites for the transcription factor SP1 
(filled arrowheads), TATA boxes (open boxes), and oriS (filled circle) are shown relative to 
the transcription start sites of ICP4 and ICP22/47 (arrow heads indicate the direction of the 
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transcription). 
 
 
 Transfection of 7b cells with 27_22_4_Or2 DNA yielded micro-plaques, but 
successful amplification of 27_22_4_Or2 virus (Figure 7a) in the absence of 
complete cell lysis was possible since viral spread could be followed by visualization 
of GFP expression in infected cells (Figure 7b). To determine if this GFP labeling 
strategy could also enable amplification of the 27_22_4_Or mutant, we also 
introduced the GFP reporter gene into the UL3-UL4 intergenic region of this mutant 
(Supplementary figure 1) under the control of the CMV promoter (which does not 
contain an embedded oriS copy). Transfection of 7b cells with DNA of this GFP-
labelled version of 27_22_4_Or revealed that only transfected cells expressed the 
GFP reporter and infection foci were not observed at any time point. We thus 
concluded that the 27_22_4_Or mutant was indeed replication-incompetent, and that 
ectopic addition of a second oriS element rescued this growth impairment, although a 
significant defect with reduced viral titers was still evident (Figure 7a). 
In an attempt to increase the replication efficiency observed with the 
27_22_4_Or2 genome, we next generated the 27_4_Or2 mutant, in which the extent 
of the IR deletion from the 27_22_4_Or mutant was reduced to maintain the ICP22 
promoter-regulatory sequences intact, thus conserving the oriS element in its natural 
location (Figure 6a and Supplementary figure 1). To facilitate the optimization of 
viral titers by monitoring of viral spread as described above, we also introduced the 
GFP reporter gene under the control of the CMV promoter, into the UL3-UL4 
intergenic region of the 27_4_Or2 mutant. Compared to 27_22_4_Or2, this mutant 
could be grown in 7b cells up to significantly higher titers (Figure 7a and 8a). 
Interestingly, GFP expression driven by the CMV promoter was weaker compared to 
that driven by the IE4/5 promoter (Figure 7b), consistent with fact that the latter is 
more strongly activated than the former by HSV-1 proteins.  
To test if additional oriS copies could further increase viral titers, we inserted 
the IE 4/5 promoter region-GFP reporter transgene cassette ectopically in the UL3-
UL4 intergenic region of the 27_4_Or2 genome, thus adding a third oriS sequence, to 
generate the 27_4_Or3 mutant (Figure 6a and Supplementary figure 1). Compared 
to the 27_4_Or2 mutant, no significant increase in 27_4_Or3 titers could be detected 
(Figure 7a and 7c).  
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Figure 7.  Growth characteristics of non-replicative genomic HSV-1 mutants 
a. Viral replication in non-complementing and complementing cell lines was determined 
following infection with IE gene deletion mutants. In samples where replication was 
observed, the titer of infectious particles per milliliter (IP/ml) was measured 24 hours after 
infection. 
b. Spread of infection of 27_22_4_Or, 27_4_Or2 GFP and 27_4_Or3 mutants revealed by 
autofluorescence of the GFP reporter gene encoded by each mutant. 7b cells were infected at 
a multiplicity of infection (MOI) of 0,05 and photographed by fluorescent microscopy at the 
indicated time points.  
c. Replication kinetics of 27_4_Or2 (filled triangles), 27_4_Or3 (open circles) in 7b cells 
infected at a MOI of 0.05.  
 
Taken together, these results indicate that synergistic interactions between 
deletions of the oriS replication origins and deletions of the IR region, the genes 
encoding for ICP27, UL55, UL56, and the remaining ICP4 copy, provoke growth 
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impairments of HSV-1. On the other hand, adding extra oriS copies does not confer 
additional replicative advantage. 
6.3. Presence of the intact IE4/5 promoter affects the growth of HSV-1 IE 
mutants 
Although the single deletion of IE protein ICP22 from the HSV-1 genome 
does not greatly affect viral growth and viability in culture 193,194, in the context of 
multiple IE deletion mutants, ICP22 has been shown to provide growth advantages. 51 
To maintain these growth advantages while eliminating IE expression of ICP22 as 
previously described by Samaniego and coworkers 52, we deleted a 270-bp sequence 
containing the TAATGARAT elements from the ICP22 IE4/5 promoter in the 
27_4_Or2 genome, thus generating the 27_4_Or2_β22 mutant (Figure 6a and 6b).  
Viral stocks of 27_22_4_Or2, 27_4_Or2, and 27_4_Or2_β22 were then 
prepared to perform multi-cycle growth kinetics (Figure 8a) for a more detailed 
analysis of the effect of modulating ICP22 expression via modifications of the IE4/5 
promoter region in our multiply deleted genomes. As expected, elimination of the 
IE4/5 promoter region in 27_22_4_Or2 delayed peak virus yields by two days, and 
reduced titers almost 10-fold compared to those of 27_4_Or2. Modification of the 
IE4/5 promoter region to convert ICP22 expression from IE to E kinetics in 
27_4_Or2_β22 resulted in peak virus yields one day before that of 27_22_4_Or2 and 
with more than a 3-fold increase. While cultures infected by either 27_4_Or2 or 
27_4_Or2_β22 showed cytopathic effects in more than 95% of the cells by 4 and 5 
days respectively, those infected by 27_22_4_Or2 did not show cytopathic effects at 
the same multiplicity of infection (0.05 infective particles/cell). In the permissive 7b 
cell line, all of the mutants exhibited slower growth kinetics and lower peak viral 
titers compared to HSV-1 WT, indicating incomplete complementation by this cell 
line. 
Since the IE4/5 promoter is present in two inverted copies upstream of both 
the ICP22 and the ICP47 genes (Figure 6b), US-isomerization events during viral 
replication could revert the TAATGARAT-deleted ICP22 promoter in our 
27_4_Or2_β22 mutant by recombination with the wild-type copy upstream of the 
ICP47 gene. Since our mutant genomes are also deleted for the IR region, we 
predicted that US-isomerization is unlikely, but to rule out this possibility we next 
constructed a double deletion mutant in which we also eliminated the TAATGARAT 
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elements from the ICP47 IE4/5 promoter of 27_4_Or2_β22, thus generating the 
27_4_Or2_β22_ β47 mutant (Figure 6a). Multi-cycle growth kinetics in 7b cells 
comparing 27_4_Or2_β22 and 27_4_Or2_β22_β47 (Figure 8b) revealed highly 
similar growth curves, indicating that isomerization-mediated restoration of the wild-
type IE4/5 promoter at the ICP22 locus in 27_4_Or2_β22 does not occur. 
 
 
Figure 8.  Comparison of growth kinetics of non-replicative genomic HSV-1 mutants 
a. Replication kinetics of HSV-1 WT (solid squares) in Vero cells and 27_22_4_Or2 (open 
triangles), 27_4_Or2 (filled triangles) and 27_4_Or2_β22 (filled diamonds) in 7b cells 
infected at a MOI of 0.05.  
b. Replication kinetics 27_4_Or2_β22 (filled diamonds) and 27_4_Or2_β22_ β47 (open 
diamonds) in 7b cells infected at a MOI of 0.05. 
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nonreplicative genomic HSV-1 vector deleted for 23 kb of viral genome sequences in 
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27_4_Or2_β22 vector do not seriously impair vector production. 
6.4. Human frataxin expression from a reduced genomic FXN-reporter 
construct 
For the generation of a recombinant herpes virus vector for long-lasting 
neurological gene therapy of Friedreich’s ataxia (FRDA), our second goal was to 
construct a human FXN transgene which fits within the cargo size limit of the 
27_4_Or2_β22 vector while retaining all the regulatory elements necessary for 
physiological expression.  
Starting from our BAC plasmid encoding the human FXN genomic locus 
(FXN-WT) 163, we generated two progressively deleted constructs, resulting in the 
decrease of the FXN transgene cassette from 135 kb down to 20 kb. We first 
eliminated 42.51 kb of the 5’ upstream region to generate the FXN-p vector, which 
maintains 5 kb of the 5’ upstream sequence described as containing the promoter 
regulatory elements necessary for physiological control of the FXN gene expression 
(Figure 9a). 111 Subsequent modifications were made as described in Methods to 
reduce the transgene down to 20 kb, resulting in the FXNinlZ construct which 
comprises the 5 kb promoter, FXN exon 1, intron 1 and a partial cDNA encoding 
exons 2 to 5a. To more easily monitor FXN transgene levels in expression studies we 
incorporated the lacZ reporter gene to be co-expressed via a 2A peptide cassette 195,196  
located at the 3’ end of the FXN open reading frame (Figure 9a). Correctly modified 
clones for the two generated constructs were confirmed by BamHI digestion followed 
by electrophoresis. Deletion boundaries were further confirmed by DNA sequencing 
analysis. 
Recently, Xia and co-workers identified two novel tissue-specific FXN 
isoforms (II and III), which may contribute to the pathological mechanism of 
Friedreich’s ataxia.116 These transcript variants have been described to arise from 
differential processing within the first intron, their remaining structure being identical 
from exons 2 to 5. Of particular relevance to our interest in gene therapy for the 
neurological aspects of FRDA, isoform II appears to be specifically expressed in 
nervous tissue. To evaluate if our reduced FXN transgene constructs maintain the 
regulatory elements necessary for alternative splicing of human FXN, we transfected 
mouse neuroblastoma cells (Neuro-2a) with each of the three FXN constructs and 
compared lysates of these samples to those from non transfected Neuro-2a cells and 
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the human neuroblastoma cell line SH-SY5Y as a positive control for human 
neuronal FXN isoforms. Using human isoform-specific primer pairs for reverse 
transcription polymerase chain reaction (RT-PCR) analysis, we were able to detect 
both the major FXN splice isoform (FXN-I) as well as the neuron-specific splice 
isoform (FXN-II) in Neuro-2a cells transfected by the three FXN constructs (Figure 
9b), confirming that our reduced transgenes containing intron 1 maintain the desired 
splicing regulation for neuronal gene therapy. 
We next analysed human FXN protein expression in mouse Neuro-2a cells 
transfected with our FXN transgenes (Figure 9c). Western blots of lysates from cells 
transfected with FXN-WT and FXNinlZ revealed three forms of FXN not present in 
non-transfected Neuro-2a cells (mock) corresponding to the precursor, intermediate 
and mature forms; as expected, migration of the bands in lysates from FXNinlZ-
transfected cells was retarded with respect to those in the FXN-WT samples due to 
the 22 amino acid C-terminal fusion to the 2A peptide sequence. In FXNinlZ samples 
a full-length translation product (hFxn-2A-βgal) can be detected, indicating that 2A 
peptide cleavage is incomplete. We confirmed that the β-Galactosidase reporter was 
functional by X-Gal staining of FXNinlZ-transfected Neuro-2a cells (Figure 9d). 
These results indicate that a reduced version of the FXN genomic locus, 
comprising the 5 kb promoter, FXN cDNA and the complete sequence of intron 1, 
maintains the regulatory elements necessary to express the frataxin isoforms normally 
found in neurons. Co-expression of the FXN-β-Galactosidase reporter in this 
transgene using the 2A peptide system offers an alternative means to monitor vector 
transduction. 
6.5. Human frataxin expression in cultured dorsal root ganglion neurons 
transduced by the FXNinlZ non-replicative genomic HSV-1 derived vector 
The third goal for the generation of a gene therapy vector targeting dorsal root 
ganglia (DRG) for FRDA was the construction of the 27_4_Or2_β22 vector carrying 
the FXNinlZ transgene. With this aim, as described in Methods, we used Cre/loxP-
mediated recombination to introduce the FXNinlZ construct or a reporter gene 
expression cassette consisting of the CMV promoter and the GFP gene into the UL3-
UL4 intergenic region of the 27_4_Or2_β22 vector thus generating the 
27_4_Or2_β22 FXNinlZ vector and the 27_4_Or2_β22 GFP control vector 
respectively (Figure 10a).  
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Figure 9. Human FXN expression from a size-reduced FXN genomic transgene. 
a. Schematic (not to scale) of the transgenic cassettes encoding: the 80kb human FXN locus 
within a 135-kb genomic DNA fragment (top, FXN-WT), showing the FXN promoter 
(FXNp, black arrowed box) and exons 1 to 6 (black vertical boxes); a reduced transgene 
(middle, FXN-p) with all 5’ upstream sequences deleted except for the 5kb promoter (black 
arrowed box, FXNp); a reduced transgene (bottom, FXNinlZ) with the 5kb promoter, exon 1, 
intron 1 and a partial cDNA encoding exons 2-5a fused in-frame to the E.coli lacZ reporter 
gene (open arrowed box) via the 2A linker peptide (grey arrowed box). All FXN constructs 
described in this study also contain the green fluorescent protein reporter gene (hatched 
arrowed box, GFP).  
b. RT-PCR detection of human FXN isoforms I and II in total mRNA prepared 48 hours after 
transfection of Neuro-2a cells with FXN-WT, FXN-mp and FXNinlZ DNA. The human 
neuroblastoma cell line (SH-SY5Y) was used as a positive control for human FXN and non 
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transduced Neuro-2a as negative control. Transduction efficiency and sample loading were 
monitored by detection of GFP and β-Actin respectively. 
c. Western blot of extracts derived from Neuro-2a cells 48h after transfection with FXN-WT 
and FXNinlZ DNA. Incubation of the blot with human FXN-specific antibody revealed the 
three human FXN forms fused to the 2A peptide (precursor-2A, intermediate-2A and mature-
2A) expressed by FXNinlZ with a lower mobility compared to those expressed by FXN-WT. 
Non transfected Neuro-2a (Mock) were used as negative controls for human FXN expression. 
Uncleaved FXNinlZ protein (hFXN-2A-βGAL) expressed by FXNinlZ can be also detected. 
As controls for transfection efficiency and loading, blots were also incubated with antibodies 
specific for GFP and β-Actin respectively. Numbers to the right indicate the molecular 
weight (kDa) of protein marker standards.  
d. Histochemical staining of Neuro-2a cells with X-Gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) following transfection with FXN-WT and FXNinlZ DNA. Enzymatic β-
Galactosidase activity is clearly evident in cells transduced by FXNinlZ (right) but not by 
FXN-WT (left). 
 
 
PCR analysis and DNA sequencing confirmed correct recombinant junctions 
for the two generated vectors (Supplementary figure 2) which were then propagated 
and titered in the ICP4/ICP27-complementing 7b cell line. Large laboratory-scale 
cultures were concentrated and purified to yield 0.5 ml of each vector (Figure 10a), 
with titers of 108 plaque-forming units (pfu) per millilitre (27_4_Or2_β22 GFP) and 
5x107 pfu/ml (27_4_Or2_β22 FXNinlZ). 
Following transport of wild-type HSV-1 into sensory neurons, the virus enters 
a latent state in which nearly all of the viral genome is silenced, and expression is 
restricted to a single locus which produces the latency-associated transcripts. Many 
nonreplicative genomic HSV-1 vectors currently employ transgene cassettes with 
viral immediate-early promoters which direct strong expression, but which is 
transient and can be subject to silencing in spinal ganglia.37,66 We previously 
demonstrated that while such silencing of the IE4/5 promoter occurs in HSV-1 
amplicon vectors injected into the adult mouse cerebellum, transgene expression 
driven from the FXN genomic locus was persistent.164 
 To investigate whether FXN genomic sequences can also provide sustained 
transgene expression from nonreplicative genomic HSV-1 vectors in DRG, we 
compared the expression of the FXNinlZ transgene (driven by the FXN promoter) to 
the expression of a GFP reporter gene driven by the CMV promoter after 
transduction of primary rat DRG neurons with our two vectors (27_4_Or2_β22 
FXNinlZ or the 27_4_Or2_β22 GFP control vector) using a multiplicity of infection 
(MOI) of 1. RT-PCR analysis showed expression of FXNinlZ mRNA at 2 days post 
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infection (dpi) which increased at 6 dpi (Figure 10b, first 2 lanes). In contrast, GFP 
gene expression of the control vector was high at 2 dpi but decreased to almost 
undetectable levels at 7 dpi (Figure 10b, lanes 3 and 4). The opposing expression 
patterns of the two vectors were confirmed by real-time RT-PCR (qRT-PCR) 
measurements at the same time points (Figure 10c and 10d). 
 
 
 
Figure 10. Transgene expression by FXN genomic sequences compared to that driven 
by the viral promoter during 1 week in cultured dorsal root ganglion neurons. 
 
a. Schematic showing the 27_4_Or2_β22GFP and 27_4_Or2_β22 FXNinlZ replication 
defective HSV-1 vectors. The control vector 27_4_Or2_β22 GFP contains a CMV promoter-
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GFP expression cassette introduced between the UL3 and UL4 genes located in the unique 
long region of HSV-1 genome, whereas the 27_4_Or2_β22 FXNinlZ vector contains the 
FXNinlZ transgene under the control of the 5kb FXN promoter (FXNp) at the same insertion 
site. Large black boxes represent the HSV-1 sequence deletion from the UL54 gene up to the 
oriS copy of the IR sequence and small black boxes represent the ICP4 gene deletion. 
Hatched boxes represent the ICP22 promoter TAATGARAT sequence deletion (β22). 
Immediate early genes deleted are listed above each deletion (Δ). Titers of viral stocks 
(plaque-forming units, PFU) are shown on the right of each construct.  
b. RT-PCR detection of the two transgenes FXNinlZ and GFP. Fetal rat DRG neurons were 
infected with 27_4_Or2_β22 FXNinlZ or 27_4_Or2_β22 GFP vector at a MOI of 1 and 
harvested 2, 6 or 7 days after infection for mRNA extraction. As negative control for both 
transgenes, mRNA extracted from non-infected cells was used. Primers specific for rat 
glyceraldehyde phosphate dehydrogenase (GAPDH) detection were used to indicate loading 
quantities.  
c. Determination of transgene mRNA levels in fetal rat DRG neurons by qRT-PCR after 
infection at a MOI of 1 with 27_4_Or2_β22 FXNinlZ or 27_4_Or2_β22 GFP vector. Infected 
cells were harvested 2, 6 or 7 days after infection for mRNA extraction. Expression 
normalized to GAPDH is shown relative to each respective vector-infected sample on day 2. 
The designations * and ** indicate statistically significant differences with p values <0.02 
and <0.005, respectively. Results shown are mean values ± standard deviation (SD) from 
three independent experiments. 
 
 
We next examined human FXN protein expression in rat DRG neurons 
infected by the 27_4_Or2_β22 FXNinlZ vector at a MOI of 1 (Figure 11). Western 
blot analysis of cell lysates made after 2 and 6 dpi using human FXN-specific 
antibody (Figure 11, top panel) revealed the three bands corresponding to the 
precursor, intermediate and mature FXN forms. As previously seen, these 
recombinant forms migrate with lower mobility than that of the endogenous human 
FXN present in human embryonic kidney (HEK293) cells due to the C-terminal 
fusion of the 22 amino acid 2A peptide. Moreover, the full-length translation product 
(frataxin-2A-βGal) could be also detected.  Consistent with the qRT-PCR data, 
frataxin and β-Galactosidase protein levels increased from 2 dpi to 6 dpi. 
Taken together, these in vitro results indicate that the human FXN genomic 
sequences present in our FXNinlZ transgene are capable of sustaining FXN 
expression in the context of a nonreplicative genomic HSV-1 vector in DRG neurons. 
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Figure 11. Human FXN protein expression after infection of cultured dorsal root 
ganglion neurons with the 27_4_Or2_β22 FXNinlZ vector. 
 
Western blot of extracts derived from cultured fetal rat DRG neurons after infection with 
27_4_Or2_β22 FXNinlZ or 27_4_Or2_β22 GFP for 2 or 6 days at a MOI of 1. Incubation of 
the blot with human FXN-specific antibody revealed expression of the three human FXN 
forms fused to the 2A peptide (precursor-2A, intermediate-2A and mature-2A) by the 
27_4_Or2_β22 FXNinlZ vector. Due to the presence of the fused 2A peptide, these 
recombinant polypeptides exhibit a lower mobility compared to the three forms found in 
human embryonic kidney cells (HEK) protein extract, used as positive control for human 
FXN expression. Uncleaved full length FXNinlZ fusion protein (hFXN-2A-βGAL) expressed 
by the 27_4_Or2_β22 FXNinlZ vector can be also detected, as well as lower molecular 
weight fusion proteins containing breakdown fragments of β-Galactosidase (asterisks). 
Protein extracts were also probed with the indicated antibodies against the two reporter gene 
products β-Galactosidase (β-GAL) and GFP expressed respectively by 27_4_Or2_β22 
FXNinlZ and by 27_4_Or2_β22 GFP. Protein loading quantity was detected by using 
antibodies specific for β-Actin. Numbers to the right indicate the molecular weight (kDa) of 
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protein marker standards. 
 
6.6. Sustained in vivo expression of human FXN in rat dorsal root ganglia 1 
month after peripheral inoculation with a nonreplicative genomic HSV-1 vector 
To examine in vivo expression from our nonreplicative genomic HSV-1 
vectors, adult rats were injected 1.5 x 106 plaque forming units (pfu) of the 
27_4_Or2_β22 FXNinlZ vector or 3 x 106 pfu of the control 27_4_Or2_β22 GFP 
vector in the plantar surface of both hind paws. Total mRNA was prepared from the 
L4-6 DRG from rats sacrificed at seven or thirty days after inoculation, and analysed 
by RT-PCR using primers specific for the FXNinlZ transgene (Figure 12a). A PCR 
product with the expected electrophoretic mobility was detected in samples at both 
time points of rats injected with the FXNinlZ vector but not with the control GFP 
vector (Figure 12a). To confirm that the RT-PCR products obtained in figure 4a are 
indeed due to the expression of the human FXN transgene after retrograde transport 
from the rat hind paws to the DRG, the corresponding bands were extracted and 
analysed by DNA sequencing (Figure 12b).  
 
 
 
Figure 12. Human FXN expression in adult rat dorsal root ganglia 1 month after 
footpad inoculation with the 27_4_Or2_β22 FXNinlZ vector. 
 
a. Rats were inoculated by subcutaneous injection with the 27_4_Or2_β22 FXNinlZ vector 
or the 27_4_Or2_β22 GFP control vector. Expression of human FXN mRNA (hFXN) in rat 
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DRG was analysed by RT-PCR 7 and 30 days post injection. As a positive control (CTR+) 
for the human FXN transgene, we used total mRNA from cultured DRG neurons after 
infection for 2 days with 27_4_Or2_β22 FXNinlZ. Primers specific for rat glyceraldehyde 
phosphate dehydrogenase (GAPDH) detection were used to indicate loading quantities.  
b. Complementing DNA sequence corresponding to the protein coding region of the human 
FXN canonical transcript containing exons 1, 2, 3, 4 and 5a. Solid and dotted arrows indicate 
the two sequencing reads of the RT-PCR products from figure 12a. Boldface nucleotide 
sequences represent the binding site for the two primers used. 
 
These preliminary results of sustained FXN expression in vivo after delivery 
of a FXN transgene regulated by its natural genomic sequences are an encouraging 
indication for the possibility of FRDA gene therapy using the 27_4_Or2_β22 
FXNinlZ vector.  
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7. DISCUSSION 
 
Gene therapy is as wide a field as that of pharmacology of small molecule 
compounds, and the vastly different effects of different vectors on dosage, 
biodistribution, toxicology and pharmacokinetics should be considered. As human 
gene therapy trials demonstrating beneficial effects begin to accumulate, it is clear 
that precise transgene regulation will be essential for this field to become a clinical 
reality. When gene transfer is carried out in dividing cells, low transduction 
efficiencies and loss of cells due to toxicity can often still yield a good clinical 
outcome due to expansion of a small number of rescued cells, but in postmitotic cells 
such as neurons, not only is high transduction efficiency important, but any cell loss 
due to the treatment is permanent and should therefore be minimized. Significantly, 
frataxin overexpression has been observed to be toxic in cultured fibroblasts 126, and 
in a Drosophila model, to provoke deleterious effects at biochemical, physiological 
and developmental levels 127, underlining the importance of controlling FXN levels in 
FRDA gene therapy approaches. Thus, efficacious treatment of FRDA patients using 
FXN-encoding viral vectors will require sustained and physiological expression from 
the therapeutic transgene, an unresolved challenge in gene therapy so far. 
7.1. Nonessential elements of the HSV-1 IE4/5 promoter region play a 
critical role in the viability of multiply deleted nonreplicative HSV-1 
genomic vectors 
The most rapid technological advances in viral vectors for gene delivery, 
especially in the clinic 197, have been made by vectors derived from viruses such as 
adenoviruses, retroviruses, lentiviruses, and adeno-associated viruses, which is 
understandable since their small genomes have simplified their comprehension and 
manipulation. However, there is now increasingly a need of larger capacity vectors 
able to deliver multiple transgenes or to encode genomic regulatory regions. With this 
aim, in the present study we have generated high capacity nonreplicative genomic 
HSV-1 vectors deleted for up to 24 kb of viral genome sequences in which transgenes 
can be inserted by Cre/loxP-mediated recombination into the vector-encoding 
bacterial artificial chromosome (BAC) plasmid. 
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In this study, we show that the viral growth of an HSV-1 vector deleted for 
ICP4, ICP27, UL55, UL56 and the IR sequence, in an ICP4/ICP27 complementing 
cell line, depends on the presence of the two oriS copies although addition of a third 
copy of oriS does not confer further replication advantages. A similar high capacity 
vector deleted for ICP4, ICP27, ICP0, ICP22 and the IR sequence, was however 
reported by Craft and coworkers to be able to grow in the same ICP4/ICP27 
complementing cell line in the presence of a single copy of oriS, although they 
observed that vector yield was extremely limited.198 It should be noted that this 
mutant was engineered from a parental HSV-1 strain KOS while the parental virus 
strain used in the present study was the HSV-1 strain F cloned in a BAC plasmid. 
Recent observations by Miyagawa and colleagues also suggest the requirement of 
only one copy of oriS in a deleted backbone for ICP4, ICP27, ICP0, IR and the 
TAATGARAT elements of ICP22.56 However this mutant and our mutants were 
engineered using different HSV-1 isomers and different complementing cell lines. In 
our mutants, deletion of the IR in 27_22_4_Or includes the ICP22 promoter sequence 
and the cell line used to propagate the vector did not complement the deleted copy of 
ICP0 removed with the IR. By contrast, deletion of the IR described by Miyagawa 
and colleagues included the ICP47 promoter sequence and the elimination of both 
ICP0 copies was complemented by vector amplification in cells derived from the 
U2OS cell line, which expresses an activity that can compensate for the lack of ICP0. 
Taking into account that ICP0 and ICP22 have a key role in viral genome 
transcription while ICP47 is involved in evasion of the host immune system, we 
hypothesize that the necessity for an oriS and/or the ICP22 promoter reflects the 
advantages of maintaining a synergy between the viral DNA replication machinery 
and the activation of the viral genome transcription by the IE genes, in order to retain 
the growth capacity of multiply deleted genomic vectors. 
In agreement with previous studies showing the growth advantages that 
ICP22 confers to multiply deleted vectors 49,51, we show that the reconstitution of the 
entire ICP22 IE4/5 promoter region at its natural location in the IR, not only reverts 
the replication failure caused by additional deletion of ICP4, ICP27, UL55 and UL56, 
but also significantly improves titers compared to the ectopic addition of a single oriS 
sequence. Whether the growth defect of the 27_22_4_Or mutant can be rescued by 
reconstitution of the ICP22 promoter without the oriS is difficult to determine since 
the oriS sequence is embedded in the ICP22 promoter region. One study has shown 
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that deletion of the oriS sequence from the IE4/5 promoter does not drastically affect 
expression of a linked luciferase reporter gene 199 but whether this can be extrapolated 
to the independence of ICP22 expression on oriS remains to be tested. 
Supporting previous observations of Samaniego and coworkers 52, we have 
also confirmed that deletion of the TAATGARAT elements of the ICP22 IE4/5 
promoter to convert ICP22 expression from immediate-early to early kinetics, 
maintains ICP22 growth-supporting functions and that additional deletion of the 
TAATGARAT elements of the ICP47 IE4/5 promoter also does not interfere with the 
replication capacity of multiply deleted vectors. 
Half of the HSV-1 genome, comprising more than 40 genes, has been 
described as non-essential for viral replication in cell culture. Deletions of these 
genome sequences have been individually studied and described as non-essential in 
the context of a wild-type HSV-1 backbone. Notwithstanding, combination of non-
essential deletions may lead to synergistic lethal effects reflecting essential functions 
resulting from interactions among these gene products.  
The large genome and slow replication of multiply deleted HSV-1 vectors 
present technical challenges for their manipulation and further modification. A key 
step in the development of HSV-1 vectors was the cloning of the entire viral genome 
as a BAC vector and its use for in vitro site-directed mutagenesis. However 
complementation of large genome sequence deletions through generation of 
complementing cell lines expressing these sequences have not been achieved so far. 
In order to generate high capacity non-replicative genomic vectors that maintain their 
amplification capacity there is a clear need of rapidly generation of stable and 
efficient complementing cell lines. 
7.2. A reduced FXN genomic transgene maintains the elements necessary 
to undergo physiological neuronal regulation 
Although the transgene capacity achieved in our vectors is almost 24 kb, 
which widely exceeds that of most viral vectors in current use, it is insufficient to 
accommodate the entire FXN genomic locus, previously demonstrated to direct 
longterm expression in the adult mouse cerebellum.164 Therefore we have instead 
inserted in our vectors, a reduced FXN genomic transgene comprising the 5 kb 
promoter and a cDNA which includes the complete sequence of intron 1, which has 
previously been shown to give rise to nervous system transcript variants of FXN. We 
Discussion 
 91 
have confirmed that our reduced transgene does indeed support sustained expression 
of both the canonical FXN I isoform as well as the nervous system-specific FXN II 
isoform after delivery into dorsal root ganglia. Moreover, detection of the precursor, 
intermediate and mature FXN forms indicate successful translation and mitochondrial 
processing of transgenic frataxin. Potential gene therapies to treat FRDA 
cardiomyopathy160,161 use vectors containing the cDNA which encodes only the 
canonical FXN I isoform. However the possibility of a significant contribution of the 
other isoforms to the pathology of FRDA cannot be ignored. The availability of our 
reduced FXN transgene in a neurotropic viral vector will facilitate the further 
identification of functional elements in FXN locus important for the regulation of 
frataxin in the nervous system. 
7.3. Native regulatory elements conserved in a reduced FXN genomic 
transgene sustain FXN expression in the context of non-replicative HSV-1 
genomic vector in DRG neurons  
As mentioned in this study, one of the important issues to be addressed in the 
use of viral vectors for gene delivery is the maintenance of transgene expression. Of 
special relevance, the role of transgene regulatory sequences and their interaction 
with both viral as well as cellular proteins are known to be important.  
In the context of non-replicative genomic HSV-1 vectors, virus-derived 
promoters with immediate early kinetics have been used to drive strong and transient 
transgene expression. Thus, these promoters are potential tools for short-term 
transgene expression in a wide range of cell types and can serve to generate marker 
transgenes to monitor the distribution and spread of recombinant viruses. Conversely, 
latency-associated promoters have been used to achieve persistent transgene 
expression from HSV-1 genomic vectors in neurons. 37,200 Native cellular regulatory 
regions have been less studied for gene delivery with HSV-1 genomic vectors due to 
their large size, often extending thousands of base pairs, exceeding the limited 
capacity of these vectors to date. 
In this study, a genomic vector carrying a reduced FXN-lacZ transgene was 
first tested by infecting different types of dividing cells (data not shown). After 
infection with the recombinant virus at different time points (up to 5-6 days, mainly 
limited by overgrowth of the cells after this time) and various multiplicities of 
infection  (MOI 0.5, 1 and 5), none of the cell types tested showed lacZ enzymatic 
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activity or protein expression although vector infection could be confirmed by 
immunostaining for HSV-1 virion proteins or expression of the ICP0 protein. 
Therefore, the lack of detectable transgene expression did not simply reflect the lack 
of infected cells. Some lacZ RNA expression was observed by RT-PCR, indicating 
that only a very low level of transgene expression occurs in dividing cells infected by 
our vector. LacZ enzymatic activity was also undetectable when the HSV-1 FXN-
lacZ vector genome was transfected into dividing cells but it was clearly evident in 
dividing cells transfected with DNA encoding the FXN-lacZ transgene alone, thus 
confirming the correct functionality of this transgene, and that its silencing in the 
context of the HSV-1 FXN-lacZ vector is due to interference by the HSV-1 genome 
in dividing cells. Significantly, we have observed that the presence of the viral 
genome does not silence transgene expression in dorsal root ganglion neurons. Indeed 
the genomic elements conserved in the reduced FXN transgene appear to protect 
frataxin expression against neuronal silencing of the viral vector genome; using the 
same viral vector, we confirmed that this neuronal silencing response reduces GFP 
expression driven by the CMV promoter down to undetectable levels, in concordance 
with previous observations of transgene expression using strong viral promoters in 
nonreplicative genomic HSV-1 vectors.58,70   
Based on these preliminary studies revealing the interactions between the 
FXN transgene, the nonreplicative HSV-1 vector genome and host cell responses to 
vector infection, we propose the following hypothesis. Upon the entry of the 
recombinant vector genome into the host cell, two early events could be crucial for 
the FXN transgene expression: a gradual host immune response to the viral infection 
and the immediate introduction of virion proteins (eg VP16 and the virion host 
shutoff protein (VHS)) as well as the expression of the remaining IE vector genes.  
During this period the host immune response may reduce gene expression of all DNA 
within the cell. Since the virion proteins have been selected during evolution to 
function in spite of the host antiviral response, all the genes transactivated by these 
proteins would keep expressing, while other cellular and viral genes would be 
silenced, including the FXN transgene. In addition, the presence of viral proteins such 
as VHS, which reduce host translation to favour viral protein synthesis, could further 
impair FXN transgene expression. It should be noted that these processes could be 
stimulated in mitotic cells by factors associated with cell division thus further 
promoting the FXN transgene silencing. Conversely, in DRG neurons the IE and 
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virion proteins present upon infection would eventually degrade due to the lack of 
cell division and cellular transactivation of IE or other viral gene expression. 
Moreover, since the vector genome is transported to the DRG neurons along axons, 
virion proteins like VP16 and VHS may not reach the DRG neurons in the same 
amounts as in infected dividing cells.  
In DRG neurons, apart from the general host antiviral response, there are 
specific anti-HSV-1 responses, such as the miRNA against ICP0 expression (miR-
138)203, which promotes establishment of the vector genome quiescent state and thus 
the recovery of normal cellular activity. The transgene, which contains cellular 
regulatory elements, would then be expressed similarly to the rest of the cellular 
genome. Regulatory elements of the FXN transgene, which normally direct cellular 
epigenetic modifications for active gene expression, could thus counteract the cellular 
silencing of the rest of the viral genome. 
7.4. In vivo delivery and sustained expression of a reduced FXN genomic 
transgene by a non-replicative genomic HSV-1 vector in dorsal root 
ganglia 
To date gene therapy of Friedreich’s ataxia has been explored with only a few 
types of vectors. 201 It is important that development and evaluation of all of these 
continue to be supported since different aspects of the same disease may be better 
treated by different vector types and delivery strategies. For the cardiomyopathy 
associated with FRDA, AAV-derived vectors have shown promising efficacy in 
mouse models when administered by intravenous160 or intraperitoneal injection.161 In 
the latter case, application for the neurological aspects of FRDA were considered, 
since these vectors could be detected in the brain when very high doses were used. 
However, given the elevated number of host cells being genetically modified by 
vector genomes, these encouraging results now await careful studies of 
biodistribution and biotoxicity. In a more recent study, intravenous injection of FXN 
mRNA encapsulated in lipid nanoparticles was shown to increase liver frataxin levels 
in mice and some expression could be detected in DRG neurons if the nanoparticles 
were administered by intrathecal delivery.202 These promising observations open the 
possibility of using easily manufactured nanoparticles although the requirement for 
repeated intrathecal injections due to their short persistence of therapeutic effect 
remains an obstacle to overcome before translation to the clinic. 
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In our approach to neurological gene therapy of FRDA we aim to target the 
DRG neurons using a non invasive gene delivery strategy already validated to be safe 
in human clinical trials. 53 Using the rat footpad inoculation model we have confirmed 
that our HSV-1 vector preserves the capacity of retrograde axonal transport and gene 
delivery into DRG neurons, one of the first sites of neurodegeneration in FRDA. In 
these tissues our reduced FXN transgene supported sustained human FXN expression 
similar to our previous observations with the entire FXN locus in the mouse 
cerebellum.164 Taken together, the data in this present work urge a more extensive 
study of our reduced genomic FXN vector in an FRDA animal model to test efficacy 
and safety. The high capacity genomic HSV-1 vector generated can be further used to 
deliver other transgenes for alternative gene therapy strategies of the DRG.  
 
 
  
 
CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 97 
8. CONCLUSIONS 	  
The conclusions drawn from this work can be summarized as follows:	  
 
1. Within the herpes simplex virus type-1	   (HSV-1) genome the non-essential 
sequences comprising oriS and the ICP22 gene play a critical role in the 
growth of multiply deleted nonreplicative HSV-1 genomic vectors. 
 
2. A nonreplicative HSV-1 genomic vector deleted for 23 kb, which include the 
sequences between the ICP27 gene and the TAATGARAT motifs of the 
ICP22 promoter and the remaining ICP4 gene sequence, can be produced at 
high titers and preserves the capacity of retrograde axonal transport and gene 
delivery into dorsal root ganglion (DRG) neurons. 
 
3. A reduced human FXN genomic transgene, comprising the 5 kb promoter and 
a complementary DNA which includes the complete sequence of intron 1, 
maintains the elements necessary to direct physiological alternative splicing 
and protein maturation in neurons. 
 
4. Native regulatory elements conserved in a reduced human FXN genomic 
transgene sustain FXN expression in the context of a nonreplicative HSV-1 
genomic vector in DRG neurons in vitro and in vivo. 
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CONCLUSIONES 
 
Las conclusiones extraídas de este trabajo son las siguientes: 
 
1. El origen de replicación (oriS) y el gen ICP22, definidos como secuencias no 
esenciales del virus del herpes simple tipo 1 (VHS-1), desempeñan un papel 
crítico en el crecimiento de los vectores genómicos no replicativos de 
deleción múltiple derivados a partir del VHS-1. 
 
2. El vector genómico no replicativo derivado del VHS-1 cuya deleción de 23 kb 
elimina las secuencias comprendidas entre el gen ICP27 y los motivos 
TAATGARAT del promotor del gen ICP22, así como la secuencia de la 
segunda copia del gen ICP4, se produce a altos títulos virales conservando 
tanto la capacidad de transporte axonal retrogrado así como de entrega del 
transgen en neuronas de los ganglios de la raíz dorsal. 
 
3. La versión reducida del locus genómico humano de FXN que consiste en el 
promotor de 5 kb, la secuencia del ADN complementario y la secuencia 
completa del intrón 1, contiene las secuencias necesarias tanto para el 
‘splicing’ alternativo como para la maduración de FXN en neuronas. 
 
4. El transgen de FXN generado, clonado en el vector genómico no replicativo 
derivado de VHS-1, contiene las secuencias y elementos reguladores 
necesarios  para la expresión sostenida de FXN en neuronas de los ganglios de 
la raíz dorsal. 
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Figure S1. Schematic of the construction of 27_22_4_Or GFP, 27_4_Or2 GFP, 
27_22_4_Or2 and 27_4_Or3 
Schematic representation of Cre recombinase-mediated single insertion of the fluorescent 
protein reporter gene (GFP) or the double insertion of the GFP and the HSV-1 origin of 
replication (oriS) sequence, at one of the loxP sites flanking the BAC vector bacterial 
sequences (BAC), which are located in the UL3-UL4 intergenic region of the 27_22_4_Or and 
27_4_Or2 BAC DNAs. Dashed lines represent the two possible recombination events at 
either of the loxP sites of the HSV-1 BACs. Two shuttle plasmids were used: the pLCG 
plasmid, used for the single insertion of the the cytomegalovirus immediate early promoter 
(CMVp)-GFP transgene cassette to generate the vectors 27_22_4_Or GFP and 27_4_Or2 
GFP, and the pHG plasmid, used for the simultaneous insertion of oriS and the immediate 
early ICP22/47 promoter (IE4/5p)-GFP transgene cassette to generate the vectors 
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27_22_4_Or2 and 27_4_Or3. Both shuttle plasmids contain a loxP site (filled arrowhead); 
the beta-lactamase gene (ampR, open box); the R6Kγ–ori (blue circle) which enables 
replication only when the π protein is supplied in trans; and the GFP reporter gene driven by 
the CMV promoter (CMVp) in the pLCG plasmid or driven by the IE4/5 promoter (IE4/5p, 
which includes the oriS sequence; filled circle enclosed by a box) in the pHG plasmid. The 
pHG plasmid contains in addition the HSV-1 packaging signal (open diamond). The 
temperature-sensitive (ts) helper plasmid pCTP-T contains a pSC101-derived thermosensitive 
replication origin (orange circle); the TcR gene conferring tetracycline resistance (dark blue 
box) for tetracycline-inducible Cre expression (light and dark green boxes); and PIR (grey 
box), the pir gene which expresses the π protein to support the replication of the co-
introduced plasmids containing the R6Kγ-ori.  
 
	  	  
Figure S2. Schematic (not to the scale) of the construction of FXN-p and FXNinlZ.  
a. Schematic representation of FXN-p construction. Starting from the FXN-WT BAC 
plasmid we inserted a cassette encoding a kanamycin resistance gene (KanR; grey arrowed 
box) and a flanking loxP511 site (black arrow) in the 5’ region upstream of the ATG start 
codon of the human FXN gene by Red/ET homologous recombination (dashed lines). The 
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KanR gene was then removed by Cre-mediated recombination (solid lines) between the 
introduced loxP511 site and another located at the boundary between the BAC vector and the 
5’ end of the FXN. The seven exons of the FXN are marked as black vertical lines.  
b. Schematic representation of FXNinlZ construction. Starting from the FXN-p BAC plasmid 
we inserted by Red/ET homologous recombination (dashed lines) a cassette encoding a 
zeocin resistance gene (ZeoR; grey arrowed box) and the sacB gene (small open arrowed box) 
to delete all of the genomic insert sequences 3’ to FXN exon 2 up to the sacB gene located 
within the BAC vector. In a second round of Red/ET homologous recombination, we next 
replaced the ZeoR gene with the F2ALRK cassette which encodes the FXN cDNA from exon 
2 to 5a (FXN cDNA 2-5a; black vertical box), the Porcine teschovirus-1 2A sequence (2A; 
grey hatched box), the Escherichia coli lacZ gene (open arrowed box), the polyadenylation 
signal (pA; open box), a loxP site (black arrow), a kanamycin resistance gene (KanR)- 
encoding cassette (grey arrowed box) and the sacB gene (small open arrowed box). The KanR 
gene was then removed by Cre-mediated recombination (solid lines) between the introduced 
loxP site and another located in the BAC vector, 3’ to the sacB gene. The resulting FXN 
reduced version includes the 5 kb promoter and the FXN cDNA with the inclusion of intron 1 
(FXN E1I12-5a; open arrowed box with black vertical lines representing exon 1 and cDNA 
2-5a). 	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